

#### Treating lateral epicondylitis with corticosteroid injections or non-electrotherapeutical physiotherapy: a systematic review

Journal:	BMJ Open						
Manuscript ID:	bmjopen-2013-003564						
Article Type:	Research						
Date Submitted by the Author:	09-Jul-2013						
Complete List of Authors:	Olaussen, Morten; University of Oslo, Department of General Practice Holmedal, Oeystein; University of Oslo, Department of General Practice Lindbaek, Morten; University of Oslo, Department of General Practice Brage, Soeren; University of Oslo, Department of Community Health Solvang, Hiroko; University of Oslo, Department of General Practice						
<b>Primary Subject Heading</b> :	Sports and exercise medicine						
Secondary Subject Heading:	General practice / Family practice						
Keywords:	SPORTS MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, Elbow & shoulder < ORTHOPAEDIC & TRAUMA SURGERY						



### Abstract

#### Objectives

To evaluate the efficacy of corticosteroid injection and non-electrotherapeutic physiotherapy, commonly used treatments for lateral epicondylitis, but for which the scientific evidence remains uncertain.

#### Design

Systematic review.

#### Setting

n/a

#### **Participants**

We searched five databases in September 2012 for randomized, controlled studies with a minimum quality rating. Of 640 studies retrieved, eleven were included, representing 1161 patients of both sexes and all ages.

#### Interventions

Corticosteroid injection and non-electrotherapeutic physiotherapy.

#### **Outcome measures**

Relative risk (RR) or standardised mean difference (SMD) for overall improvement, pain and grip strength at 4 to 12, 26 and 52 weeks follow-up.

#### Results

Corticosteroid injection gave a short-term reduction in pain vs no intervention or NSAIDs (SMD -1.43, 95% CI -1.64 to -1.23). At intermediate follow-up, we found an increase in pain

(SMD 0.32, 95% CI 0.13 to 0.51), reduction in grip-strength (SMD -0.48, 95% CI -0.73 to - 0.24), and negative effect on overall improvement effect (RR 0.66 (0.53 to 0.81). For corticosteroid injection vs lidocaine injection, evidence was conflicting. At long-term follow up, there was no difference on overall improvement and grip strength, with conflicting evidence for pain. Manipulation and exercise vs no intervention showed beneficial effect at short-term follow-up (overall improvement RR 2.75, 95% CI 1.30 to 5.82), but no significant difference at intermediate or long-term. We found moderate evidence for a short- and long-term effect of eccentric exercise and stretching vs no intervention. For exercise vs no intervention and eccentric or concentric exercise and stretching vs stretching alone, we found moderate evidence of no short-term effect.

#### Conclusions

Corticosteroid injections have a short-term beneficial effect on lateral epicondylitis, but a negative effect at intermediate term. Evidence on long-term effect is conflicting. Manipulation and exercise and exercise and stretching have a short-term effect, the latter also a long-term effect.

#### **Trial registration**

None.

## **Article summary**

#### Article focus

• What is the current evidence for the effect of treating lateral epicondylitis with corticosteroid injection or non-electrotherapeutic physiotherapy?

#### Key Messages

- Corticosteroid injections have a short-term beneficial effect on lateral epicondylitis, but a negative effect at intermediate term. Evidence on long-term effect is conflicting.
- There is evidence for a short-term effect of manipulation and exercise and exercise and stretching, for the latter also on long-term.

#### Strengths and limitations of this review

• We found overall few good quality studies on these treatments, making a metaanalysis possible only for a few studies and outcomes. Lateral epicondylitis of the elbow is a frequently encountered complaint in general practice with an incidence of 4 - 7 per 1000 per year [1-3]. It is characterised by pain and tenderness over the lateral humeral epicondyle and pain on resisted dorsiflexion and radial deviation of the wrist. It is usually a self-limiting condition, often resolving in 6 to 12 months regardless of treatment, but complaints may last up to 2 years or longer [4]. Due to considerable pain and discomfort, many patients need time off from work.

Most authors attribute the condition to a lesion in the short radial extensor muscle [1, 5]. A recent study has found evidence of reduced hyperaemia measured with spectral and colour Doppler in lateral epicondylitis treated with corticosteroid injection, suggesting evidence of an inflammatory component [6]. Others, finding little evidence of inflammation have proposed the term "lateral epicondylalgia" for the condition [7].

Most patients with lateral epicondylitis are treated in general practice, and although a large number of treatments are in use, there is no consensus on which treatments are most effective. The Cochrane Library has reviewed several treatments. For topical NSAIDs and NSAIDs taken orally, the conclusion is that both have a short term effect [8]. For extracorporeal shockwave therapy, a review of nine studies including 1000 patients found this treatment to have no effect [9]. For acupuncture [10], deep friction massage [11], orthosis [12] and surgery [13] the reviews were inconclusive due to few and methodologically weak studies.

Four review articles have been published on the effect of corticosteroid injections [14-17]. They found a short-term effect of corticosteroid injection, but no proven long-term effect, and one review found evidence of a negative long-term effect [15]. However, some of the reviews included non-controlled studies [14, 16] and non-randomised studies [16]. In one

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ Open**

Five reviews of physiotherapeutic interventions show that there are few published studies on the effect of non-electrotherapeutic treatment, and many have methodological weaknesses [16, 18-21]. Bisset et al. [18] found evidence that manipulation and exercise had a short term effect. Four other reviews [16, 19-21] found short-term effects of mobilisation, manipulation and exercise. Three of these reviews included non-randomised or non-controlled studies [16, 19, 21]. Most previous systematic reviews have included electrotherapeutic physiotherapy such as ultrasound and extra-corporeal shockwave [14, 16, 20, 21].

Since there is no established, well-documented treatment to which new treatments can be compared, the use of a control group is important. The natural course of the condition, where most patients eventually recover regardless of intervention, makes this even more necessary. In a comparison of two different treatments, any effect found may only reflect this natural course of recovery unless the treatments prove better than a control group with no treatment.

It has been shown that systematic reviews which include studies with low scores on internal validity may over-estimate effect sizes, thus introducing a potential bias to the review [22]. There may also be a problem using rating scales with heterogeneous criteria, including i.e. criteria related to external validity, interpretation or ethical issues [22, 23].

To address these issues, a new systematic review on non-electrotherapeutic physiotherapy and corticosteroid injection seemed warranted. We wanted to include only randomised studies with a control group with no treatment or studies in which the groups only differed in regards to the investigated treatment. An established quality rating scale would be

used. We also wanted to review the most current evidence on the efficacy of corticosteroid injection, since previous reviews have differing conclusions on long-term effect.

#### Objective

The aim of this review was to assess the current evidence for the efficacy of corticosteroid injection and non-electrotherapeutical physiotherapy compared with control in patients with tennis elbow.

## Methods

We followed the recommendations of the Cochrane Collaboration [24] and the PRISMA Group [25] in the search and report of this systematic review.

#### **Study selection**

We used the following inclusion criteria:

#### Study type

Randomized, controlled trials assessing treatments for lateral epicondylitis or tennis elbow were eligible for inclusion. The studies had to have at least one treatment group and one control group. We defined a control group as a group receiving no treatment (a wait-and-see approach), common treatments with expected or known moderate effect (advice, rest, NSAIDs, pain-killers) or the same treatment as the experimental group with the exception of the investigated treatment.

#### Participants

All age groups with a clinical diagnosis of lateral epicondylitis were included without restriction on gender.

#### Treatments

We searched for studies investigating or comparing the efficacy of one of the following treatments: corticosteroid injection, non-electrotherapeutic physiotherapy including stretching, mobilisation, manipulation, massage, exercise or home training. Studies on splinting, ultrasound, shock wave and other electrotherapeutic modalities were excluded.

#### Outcome measures and follow up

At least one validated, patient-centred outcome was necessary. This could include outcomes important to the patient such as pain, range of movement, grip strength, work status and relevant functional questionnaires. We included only studies done in a clinical setting with at least four-week follow-up of treatment effect. BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

#### Study quality assessment

We used the 11-item PEDro scale to assess the quality of the studies included in the review. This rating system closely resembles the Cochrane Collaboration Scoring system [24] and is based on the Delphi list, developed for quality assessment of randomised controlled trials by Verhagen et al. [26]. It has been used in several previously published reviews [15, 18, 19]. The PEDro scale assesses the internal and external validity of a study by addressing the issues of eligibility criteria, randomisation, allocation, blinding, statistics and data reporting. The reliability of this scale has been confirmed by Maher et al in 2003 [27]. The maximum score is 10, since item number one on the scale (specified eligibility criteria) is not counted.

A minimum score of 5 out of 10 points (50%) was chosen to be necessary for inclusion in the review, as inclusion of lower quality studies in a systematic review may overestimate the treatment effect of interventions [28]. Ten studies were independently assessed

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

by two researchers (MO, ØH) [29-38] and three studies were rated by both researchers together [39-41]. The final decision on PEDro score was reached by consensus.

#### Search methods for identification of studies

#### Electronic searches

From October 2009 to January 2010, we searched the following databases for publications: Medline (Ovid and PubMed), EVSCO/Cinahl, Embase, Allied and Complimentary Medicine, The Physiotherapy Evidence Database (PEDro) and the Cochrane RCT register. The searches within each database were done without restrictions on dates or languages. We used free text, not MESH terms, in these searches, and the key terms used were "tennis elbow", "lateral epicondylitis", epicondylalgia, elbow, randomised, randomized, injection, corticosteroid, and physiotherapy. The Boolean operator AND was used to link diagnostic terms and treatment where applicable. An additional search was done in September 2012 to identify any recently published studies.

#### Searching other resources

Further search was done in the reference list of articles initially considered for review.

#### Selection of studies

The searches resulted in a number of studies potentially eligible for inclusion. Titles and abstracts were then read by two researchers independently (MO,  $\emptyset$ H) and potential studies were selected based on the inclusion criteria. The final decision on inclusion was made by consensus from reading the full-text documents.

#### Data extraction and statistical analysis

The included studies were read in full text and assessed by two independent researchers (MO,

ØH). One article, published in Italian, was translated by a professional bureau [41]. A

#### **BMJ Open**

standardized set of data was extracted from each selected study and recorded using standardized forms. We calculated statistics using the statistical computing language R (www.r-project.org, The R Foundation for Statistical Computing, Vienna, Austria). We reported the results of the outcome measures for three different timings of follow-up, defined as short-term (four to 12 weeks after randomisation), intermediate term (six months after randomisation) and long-term (more than six months after randomisation). For dichotomous data, we calculated relative risk (RR) and 95% confidence intervals (CI) with the R-project library "epi.R", for continuous data the standardised mean difference (SMD) and 95% CI with the R-project library "compute.es". We pooled estimates when we found sufficient clinical and statistical homogeneity between trials using the I<sup>2</sup> statistic, defined as I<sup>2</sup> less than 65% [42].

Some studies did not report the mean, standard deviation or number of samples, which were necessary to calculate SMD. Additional calculations were then required. For Coombes [38], the median and the interquartile range (IQR) were given. We set the median as the mean value and the standard deviation was given by IQR/1.35 under the assumption of normal distribution. For Newcomer [33], the standard deviation was calculated by t-statistics obtained by the p-value and degrees of freedom. For Price [34], the t-statistics was obtained by the degrees of freedom and 95% probability. The standard deviation was estimated by the t-statistics, the mean value and upper/lower confidence intervals.

For overall improvement, a RR larger than 1 favoured treatment, and was statistically significant if the CI excluded 1. We defined the effect as large for values larger than 2 or less than 0.5, medium between 0.5 and 0.8 and between 1.25 and 2 and small for values between 0.8 and 1.0 and between 1.0 and 1.25.

For continuous data, a positive or negative SMD favoured treatment depending on the outcome measures, ie. for pain a negative SMD favoured treatment and for grip strength a

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

positive SMD favoured treatment. SMD was statistically significant if the CI excluded zero. We defined the effect as large for SMD more than 0.8, medium between 0.5 and 0.8 and small for values less than 0.5. For outcomes that could not be pooled, we graded the strength of the scientific evidence as strong (consistent findings in several high-quality randomised controlled studies), moderate (one high-quality randomised controlled study), conflicting (inconsistent finding between many studies) or no evidence [43].

#### Inter-rater reliability

The inter-rater reliability for the individual PEDro scores was assessed by calculating the intra-class correlation coefficient [44]. The R-project library "psych" was used for this calculation. A substantial inter-rater reliability was found (intra-class correlation coefficient 0.69 (0.15-0.91), p<0.01).

### Results

The search retrieved an initial 839 hits, representing 640 individual articles. The further selection process is outlined in Figure 1. 623 articles were excluded based on title and abstract in a preliminary review. 17 articles [29-37, 39, 41, 45-50] were then assessed using the full-text documents. Three were found not to be randomised controlled trials [45-47], two had a PEDro quality rating below 50% (Table 2) [37, 39] and three had a follow-up shorter than four weeks [48-50]. The additional search done in september 2012 retrieved two possible studies [40, 51], one of which was excluded for not having a control group [51]. A recently published study was also assessed [38] and a total of 11 studies were included in the final review [29-36, 38, 40, 41].

#### **Included studies**

The characteristics and details of each study are given in Table 1. The included studies represented a total population of 1161 patients. Several studies had more than one treatment

#### **BMJ Open**

The mean age of patients varied from 41 to 51 years and the female percentages varied from 35 to 63. There were large differences in duration of complaints at baseline between studies. Most had a duration of several weeks to months and only one stated a short duration [33]. Eight studies had control groups with no active treatment [29-31, 34-36, 38, 40], e.g. a wait-and-see group or NSAIDs. Two of these used lidocaine as a placebo injection [31, 34]. In the three other studies, the control and treatment groups both received similar active treatments, with the intervention group in addition receiving the treatment to be investigated [32, 33, 41].

Eight studies investigated corticosteroid injections, representing 925 patients [29-31, 33-36, 38]. Five different corticosteroids were used, with different dosages and injection techniques. The control groups received no active treatment in seven of the eight studies, in one study both the control and treatment group received additional exercise treatment [33]. Seven of the studies had a long-time follow up of 24 weeks or more [29-31, 33-35, 38].

There were few studies covering non-electrotherapeutic physiotherapy. We found five studies which could be included, representing 600 patients [29, 32, 38, 40, 41]. The treatment modalities investigated were manipulation and exercise [29, 38], concentric or eccentric exercises [32], exercise [40] and eccentric exercises with stretching [41]. Three studies had a control group with no active treatment [29, 38, 40], the other two had control groups that received stretching and orthosis respectively. Three studies [29, 38, 41] had a follow up of 24 weeks or more.

The most frequently used outcome measures were assessment of pain and grip strength. Six studies measured pain free grip strength with handheld dynamometers [29-33,

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

35]. Eight studies used a number of different questionnaires covering pain, function and disability [29-33, 35, 38, 40]. Nine studies assessed pain on a visual analogue scale or Likert-scale [29-34, 36, 38, 40], and six studies rated patient's assessment of improvement on graded scales [29, 30, 35, 36, 38, 41].

#### Risk of bias in included studies

We addressed the issues of the quality of the included studies and completeness of reported data by rating them with the PEDro scale (Table 2). Most studies used a computerized randomisation schedule, and seven of the eleven studies used concealed allocation [29-31, 35, 38, 40, 41]. Baseline comparison was done in all studies, the dropout rate was below 15% in ten studies [29, 30, 32-36, 38, 40, 41] and intention to treat analysis was stated in all studies. There was between-group analysis of at least one outcome measure in all the studies, and both point-measures and variations of outcome measures were reported in all studies.

The use of blinding was more diverse among the studies. Blinding the subject for treatment is difficult for physiotherapeutic treatments, but the use of blinded assessors reduces the risk of bias. None of the studies on physiotherapy in our review had blinded subjects or therapists, but two used blinded assessors [29, 38]. This might give biased results in the studies covering physiotherapeutic treatments.

For the eight studies on corticosteroid injection, the number using blinding was larger. There was blinding of subjects in four studies [31, 33, 34, 38], of the treating doctor in two [31, 33] and of assessors in six studies [29-31, 34, 35, 38].

In several studies the control group received some form of treatment (although similar to the treatment group) [32-34, 36, 41]. In these studies, synergistic effects between the treatments cannot be ruled out. This makes the results more difficult to interpret. Two studies had a short follow up of four and six weeks [32, 36], which for a condition usually lasting

#### **BMJ Open**

several months, reduces the clinical implication of the results. Difference in duration of complaints at baseline also complicates comparison between studies.

#### **Effects of interventions**

#### Corticosteroid injection

The efficacy of corticosteroid injection for treating lateral epicondylitis was investigated in eight studies (Table 3 and Figure 2 [52]). For short-term follow up, heterogeneity between studies made pooling of outcomes only possible for pain. For corticosteroid injection vs no intervention or NSAIDs, we found strong evidence for a beneficial effect on overall improvement and a large positive effect on pain [29, 30, 35, 36, 38]. For grip strength, we found moderate evidence for a negative effect [35]. For corticosteroid injection vs lidocaine injection, evidence was conflicting for effect on pain, with two studies showing a large positive effect (Price et al. using hydrocortisone and triamcinolone) [34] and one showing no significant difference [31]. For maximum grip strength, the evidence was also conflicting, with one study showing a large positive effect of treatment (Price et al. using triamcinolone)[34], and two studies showing no statistical difference (Lindenhovius, Price et al. using hydrocortisone) [31, 34]. For corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found moderate evidence for no significant difference on pain and grip strength [33].

At intermediate follow-up, we found sufficient homogeneity to poole estimates for overall improvement [29, 30, 38] and pain [29, 30, 35, 38] for corticosteroid injection vs. no intervention or NSAIDs. For overall improvement this showed a medium negative effect and for pain a small negative effect. For maximum grip strength, pooling of corticosteroid injection vs no intervention, NSAIDS and lidocaine showed a small negative effect [31, 34, 35]. For corticosteroid injection vs lidocaine injection, pooling of estimates was not possible due to heterogeneity. For pain, two studies showed a large negative effect (Price et al. using

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

hydrocortisone and triamcinolone)[34], and one study showed no significant difference [31], thus the evidence was conflicting. For grip strength, the evidence was also conflicting, with the same two studies showing a large negative effect [34] and one showing no significant difference [31]. For corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found moderate evidence of no significant effect on pain [33].

At long-term follow-up, pooled estimates of overall improvement showed no difference in effect of corticosteroid injection vs no intervention or NSAIDs [29, 30, 35, 38]. For pain, heterogeneity prevented pooling and we found the evidence conflicting with one study showing a large negative effect [30], and three others showing no significant difference in effect [29, 35, 38]. For grip strength, we found moderate evidence of no significant difference [35]. For corticosteroid injection vs lidocaine injection and corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found no data on long-term effect.

#### Physiotherapy

We included five studies (n=600) investigating non-electrotherapeutical physiotherapy, representing five different treatment modalities (Table 4 and Figure 3 [52]).

Two studies investigated the efficacy of manipulation and exercise vs. no intervention [29, 38]. At short-term, pooled estimates showed a large positive effect on overall improvement. For pain, pooling was not possible due to heterogeneity. We found strong evidence for a beneficial effect, for pain free grip strength we found moderate evidence for a beneficial effect. At intermediate-term, pooled estimates showed no difference between treatment and control for neither pain nor overall improvement. There was moderate evidence for no difference in pain free grip strength. At long-term, pooled estimates again showed no difference between treatment and control for either pain or improvement and we found moderate evidence for no difference in pain free grip strength.

#### **BMJ Open**

The efficacy of exercise vs no intervention was investigated in one study [40]. We found moderate evidence for no short-term difference in effect for outcomes on pain and DASH-score. There was no data on intermediate- or long-term effect.

For eccentric exercise and stretching vs stretching, investigated in one study [32], we found moderate evidence for no short-term treatment effect for outcomes on pain, pain-free grip strength and DASH-score. There was no data on intermediate- or long-term effect.

The same study also investigated the efficacy of concentric exercise and stretching vs stretching. We found moderate evidence for no short-term treatment effect for outcomes on pain, pain-free grip strength and DASH-score. There was no data on intermediate- or longterm effect.

Eccentric exercise and stretching vs no intervention was investigated in one study [41]. We found moderate evidence for a positive effect on pain and grip strength at short-term follow up. There was no data on efficacy at intermediate follow-up, but at long-term, we found moderate evidence of a positive effect on overall improvement, pain and grip strength.

## Discussion

#### Summary of main results

This review found overall evidence for a short-term beneficial effect of corticosteroid injection. At intermediate follow-up, the evidence showed an overall negative effect. For corticosteroid injection vs lidocaine injection, we found the evidence to be conflicting. At long-term follow up, the evidence suggest no difference in effect on overall improvement and grip strength, but the evidence was conflicting for pain. For manipulation and exercise vs no intervention, we found an overall beneficial effect at short term, but no significant difference at intermediate or long-term follow-up. The evidence on exercise vs no intervention showed no differences at short-term follow up. For eccentric exercise and stretching vs stretching

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

alone, the evidence showed no short-term difference in effect. The same was found for concentric exercise and stretching vs stretching. The evidence on eccentric exercise and stretching vs no intervention showed a beneficial effect at short-term and long-term, while there was no data on intermediate follow-up.

For treating lateral epicondylitis, this review showed evidence for a short-term benefit of corticosteroid injection and manipulation with exercise. Eccentric exercise and stretching showed beneficial effect both at short- and long-term follow-up.

#### Overall completeness and quality of the evidence

 There is a paucity of well-designed studies for determining the effect of nonelectrotherapeutic physiotherapy. The conclusions on the effect of these treatments are therefore limited. A comparison and review of several individual studies was only possible for one treatment modality, manipulation and exercise vs no intervention (Table 4).

We included eight studies treating a total of 925 patients with corticosteroid injections in our review. The conclusions for this treatment are more solid due to the larger number of studies, seven of which had long-term follow up. Due to differences in type of corticosteroids used, treatment regimes and outcome measures in the included studies, pooling of outcome measures was difficult. We found statistical heterogeneity for most outcomes, and pooling was only possible for a few of the outcomes and follow-ups. The long-term effect of corticosteroid injection showed conflicting results in the included studies. The large differences across the studies in duration of complaints at baseline, corticosteroids used in different dosages, and control group treatments may explain this.

The difference in duration of complaints at baseline complicates the interpretation and comparison of the results, since there might be different effects of the treatments on an epicondylitis of recent onset compared to one that has lasted several months. This is also reflected by Cook [53] who considered tendinopathy as a continuum with three stages and

#### **BMJ Open**

different characteristics and presumably treatments for each stage. Haahr [54] found that high physical strain at work, work with manual tasks, high perceived stress at baseline and a high level of pain and dysfunction seem to predict an unfavourable outcome after one year. Thus any differences in baseline characteristic for these parameters might possibly influence between-group differences of outcome.

#### Potential biases in the review process

The search process, selection of search terms and possible errors in reading and assessing the large number of articles represent a possible bias. Although we have searched several databases with a number of search terms, we may have missed some published studies. To reduce the risk of bias in the inclusion process, we used two reviewers who independently screened articles.

Our choice of inclusion criteria, especially the type of control or comparison treatment and the use of a cut-off quality score (PEDro), has important implications for the conclusions that can be drawn from this review. The efficacy of the treatments are here only compared with a control (no treatment) or to an underlying treatment that is common to both intervention groups, so no conclusion can be drawn on which of two different treatments is best.

To address the issue of publication bias, we searched two clinical trial registries: ClinicalTrial.gov (US National Institutes of Health) and Current Clinical Trials. We found no completed, unpublished studies on corticosteroid injection. Two completed studies on nonelectrotherapeutic physiotherapy were found. One from The United Kingdom completed in 2008 on manipulation with movement and one from Sweden completed in 2009 on eccentric training. We have found no published articles from these studies. Unpublished studies are not indexed in PubMed or other databases and older studies may have been conducted without

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

registration in a clinical trial registry, making it difficult to make an overall assessment of publication bias.

#### Agreements and disagreements with other reviews

Our findings agree with earlier reviews [14, 16, 17, 55]. We found consistent evidence of a beneficial short-term effect of corticosteroid injections, but evidence on the long-term effect is still conflicting. Coombes et al. [15] found in their review that corticosteroid injections have a worse outcome in the long term than most conservative interventions for tendinopathies of different locations. The included studies in our review did not allow for a similar strong conclusion on the long-term effect of corticosteroid injections. For non-electrotherapeutical physiotherapy, we agree with earlier reviews [14, 16, 18, 19, 21] that there is moderate evidence of a short-term effect of manipulation and exercise. Our review strengthens this conclusion with the inclusion of a recently published study [40]. In addition, we found moderate evidence of both short- and long-term beneficial effect of eccentric exercise and stretching.

## **Authors' conclusions**

#### Implications for practice

For lateral epicondylitis, this review found support for the use of corticosteroid injection for a short-term effect. The improvement in outcome measures was in our view of such a degree that it is clinically significant (Table 3, Figure 2). The negative intermediate effect and conflicting long-term effect make the treatment decision more difficult. Lateral epicondylitis is a self-limiting complaint that usually resolves in 6 to 12 months regardless of treatment. Thus, one could be tempted to refrain from active intervention. However, the effect of corticosteroid injection in the short term would be a strong argument for its use for many patients, even at the risk of a relapse. This could improve the ability to be at work or other

#### **BMJ Open**

physical activities. As long as the evidence for an inferior long-term effect is conflicting, we find it difficult to advice against the use of this treatment if it can reduce the patient's symptoms for some of the time the condition takes to heal. These issues should be discussed with the patient as part of deciding the best treatment for each patient. We found some support for recommending the use of manipulation with exercise and eccentric exercise with stretching.

#### Implications for research

Further randomised, controlled trials are needed to investigate the intermediate and long-term efficacy of corticosteroid injection. A meta-analysis with individual patient data from earlier studies might give more answers to the question on long-term effect. The effect of different corticosteroids, dosages and injection techniques need to be investigated.

For non-electrotherapeutical physiotherapy, more studies with a randomised, controlled design are needed. Blinding, for example by using a blinded assessor, should be apllied wherever possible. The promising results on manipulation with exercise and eccentric exercise with stretching needs further investigating.

Future studies should differentiate between acute and chronic complaints. Baseline levels of perceived pain, stress levels, handedness and presence of physical stress at work should be recorded. Standardization in the usage of outcome measures will enable data pooling and meta-analyses in future reviews. Studies investigating the combined effect of physiotherapy and corticosteroid injection treatments would also be useful. Most patients with acute lateral epicondylitis are treated in a general practice setting, and future research should be performed in such a setting.

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Erasmushogeschool

## Acknowledgements

Morten Olaussen and Oeystein Holmedal designed the study, performed the searches, read articles, decided which articles to include, performed the data extractions, interpreted the findings and wrote the main manuscript. Morten Lindbaek designed the study, decided which articles to include, interpreted the findings and revised the manuscript. Soeren Brage decided which articles to include, interpreted the findings and revised the manuscript. Hiroko Solvang did the statistical calculations and analysis, interpreted the findings and revised the manuscript.

## **Competing interests**

The authors declare that they have no competing interests.

## Funding

Our work was funded by The Fund for General Practice Research, The Norwegian Medical Association, Oslo, Norway.

## References

- Chard MD, Hazleman BL: Tennis elbow--a reappraisal. *Br J Rheumatol* 1989,28(3):186-190.
- Hamilton PG: The prevalence of humeral epicondylitis: a survey in general practice. JR CollGenPract 1986,36(291):464-465.
- Kivi P: The etiology and conservative treatment of humeral epicondylitis. ScandJRehabilMed 1983,15(1):37-41.
- Hudak PL, Cole DC, Haines AT: Understanding prognosis to improve rehabilitation: the example of lateral elbow pain. *ArchPhysMedRehabil* 1996,77(6):586-593.
- 5. Murtagh J: Tennis elbow. *AustFamPhysician* 1984,13(1):51.

#### **BMJ Open**

6.	Torp-Pedersen TE, Torp-Pedersen ST, Qvistgaard E, Bliddal H: Effect of
	glucocorticosteroid injections in tennis elbow verified on colour Doppler
	ultrasonography: evidence of inflammation. Br J Sports Med 2008, 42(12):978-982.
<i>'</i> .	Alfredson H, Lorentzon R: Chronic tendon pain: no signs of chemical inflammation
	but high concentrations of the neurotransmitter glutamate. Implications for treatment
	CurrDrug Targets 2002,3(1):43-54.
	Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft WJ: Non-
	steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults.
	Cochrane Database of Systematic Reviews 2001(4).
) <u>.</u>	Buchbinder R, Green S, Youd JM, Assendelft WJ, Barnsley L, Smidt N: Shock wave
	therapy for lateral elbow pain. Cochrane Database of Systematic Reviews 2005(4).
0.	Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft W:
	Acupuncture for lateral elbow pain. [Review] [30 refs]. Cochrane Database of
	Systematic Reviews(1):CD003527, 2002 2002(1):CD003527.
1.	Brosseau L, Casimiro L, Milne S, Robinson V, Shea B, Tugwell P, Wells G: Deep
	transverse friction massage for treating tendinitis.[update of Cochrane Database Syst
	Rev. 2002;(1):CD003528; PMID: 11869672]. [Review] [38 refs]. Cochrane Databas
	of Systematic Reviews(4):CD003528, 2002 2002(4):CD003528.
12.	Struijs PA, Smidt N, Arola H, van Dijk CN, Buchbinder R, Assendelft WJ: Orthotic
	devices for the treatment of tennis elbow. Cochrane Database of Systematic Reviews
	2002(1).
3.	Buchbinder R, Green S, Bell SN, Barnsley L, Smidt N, Assendelft WJ, Johnston RV:
	Surgery for lateral elbow pain. Cochrane Database of Systematic Reviews 2002(1).

 Barr S, Cerisola FL, Blanchard V: Effectiveness of corticosteroid injections compared with physiotherapeutic interventions for lateral epicondylitis: a systematic review. *Physiotherapy* 2009,**95(4)**:251-265.

- Coombes BK, Bisset L, Vicenzino B: Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. *Lancet* 2010,376(9754):1751-1767.
- Nimgade A, Sullivan M, Goldman R: Physiotherapy, steroid injections, or rest for lateral epicondylosis? What the evidence suggests. *Pain Pract* 2005,5(3):203-215.
- 17. Smidt N, Assendelft WJ, Van der Windt DA, Hay EM, Buchbinder R, Bouter LM:
  Corticosteroid injections for lateral epicondylitis: a systematic review. *Pain*2002,96(1-2):23-40.
- Bisset L, Paungmali A, Vicenzino B, Beller E: A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia. *BrJSports Med* 2005,39(7):411-422.
- 19. Herd CR, Meserve BB: A systematic review of the effectiveness of manipulative therapy in treating lateral epicondylalgia. *J Man Manip Ther* 2008,**16(4)**:225-237.
- Smidt N, Assendelft WJ, Arola H, Malmivaara A, Greens S, Buchbinder R, Van der Windt DA, Bouter LM: Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. *AnnMed* 2003,35(1):51-62.
- Trudel D, Duley J, Zastrow I, Kerr EW, Davidson R, MacDermid JC: Rehabilitation for patients with lateral epicondylitis: a systematic review. *J Hand Ther* 2004,17(2):243-266.
- 22. van Tulder MW, Suttorp M, Morton S, Bouter LM, Shekelle P: Empirical evidence of an association between internal validity and effect size in randomized controlled trials of low-back pain. *Spine (Phila Pa 1976)* 2009,**34(16)**:1685-1692.

#### **BMJ Open**

23.	Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality
	of controlled clinical trials. BMJ 2001,323(7303):42-46.
24.	Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions
	Version 5.0.2.: The Cochrane Collaboration; 2009.
25.	Moher D, Schulz KF, Altman DG: The CONSORT statement: revised
	recommendations for improving the quality of reports of parallel-group randomised
	trials. Lancet 2001,357(9263):1191-1194.
26.	Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild
	PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials
	for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol
	1998, <b>51(12)</b> :1235-1241.
27.	Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M: Reliability of the
	PEDro scale for rating quality of randomized controlled trials. Phys Ther
	2003,83(8):713-721.
28.	Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP:
	Does quality of reports of randomised trials affect estimates of intervention efficacy
	reported in meta-analyses? Lancet 1998,352(9128):609-613.
29.	Bisset L, Beller E, Jull G, Brooks P, Darnell R, Vicenzino B: Mobilisation with
	movement and exercise, corticosteroid injection, or wait and see for tennis elbow:
	randomised trial. <i>BMJ</i> 2006, <b>333</b> :939.
30.	Hay EM, Paterson SM, Lewis M, Hosie G, Croft P: Pragmatic randomised controlled
	trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis
	of elbow in primary care. BMJ: British Medical Journal 1999, 319(7215):964-968.
31.	Lindenhovius A, Henket M, Gilligan BP, Lozano-Calderon S, Jupiter JB, Ring D:
	Injection of dexamethasone versus placebo for lateral elbow pain: a prospective,

double-blind, randomized clinical trial. *Journal of Hand Surgery - American Volume* 2008,**33(6)**:909-919.

- 32. Martinez-Silvestrini JA, Newcomer KL, Gay RE, Schaefer MP, Kortebein P, Arendt KW: Chronic lateral epicondylitis: comparative effectiveness of a home exercise program including stretching alone versus stretching supplemented with eccentric or concentric strengthening. *Journal of hand therapy: official journal of the American Society of Hand Therapists* 2005, 18:411-419, quiz.
- 33. Newcomer KL, Laskowski ER, Idank DM, McLean TJ, Egan KS: Corticosteroid injection in early treatment of lateral epicondylitis. *Clinical journal of sport medicine: officia ljournal of the Canadian Academy of Sport Medicine* 2001,**11**:214-222.
- Price R, Sinclair H, Heinrich I, Gibson T: Local injection treatment of tennis elbow hydrocortisone, triamcinolone and lignocaine compared. *BrJRheumatol* 1991,30(1):39-44.
- 35. Smidt N, Van der Windt DA, Assendelft WJ, Deville WL, Korthals-de Bos IB, Bouter LM: Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. *Lancet* 2002,359(9307):657-662.
- 36. Toker S, Kilincoglu V, Aksakalli E, Gulcan E, Ozkan K: Short-term results of treatment of tennis elbow with anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture. *Acta Orthopaedica et Traumatologica Turcica* 2008,42:184-187.
- Tonks JH, Pai SK, Murali SR: Steroid injection therapy is the best conservative treatment for lateral epicondylitis: a prospective randomised controlled trial. *International Journal of Clinical Practice* 2007,61(2):240-246.
- Coombes BK, Bisset L, Brooks P, Khan A, Vicenzino B: Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral

#### **BMJ Open**

	epicondylalgia: a randomized controlled trial. JAMA : the journal of the American
	Medical Association 2013,309(5):461-469.
39.	Kochar M, Dogra A: Effectiveness of a specific physiotherapy regimen on patients
	with tennis elbow: Clinical study. Physiotherapy 2002,88(6):333-341.
40.	Peterson M, Butler S, Eriksson M, Svardsudd K: A randomized controlled trial of
	exercise versus wait-list in chronic tennis elbow (lateral epicondylosis). Upsala
	journal of medical sciences 2011, <b>116(4)</b> :269-279.
41.	Selvanetti A, Barrucci A, Antonaci A, Martinez P, Marra S, Necozione S: Role of the
	eccentric exercise in the functional reeducation of lateral epicondylitis: a randomised
	controlled clinical trial. Medicina dello Sport 2003,56:103-113.
42.	Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-
	analyses. BMJ 2003,327(7414):557-560.
43.	van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method guidelines for
	systematic reviews in the cochrane collaboration back review group. Spine
	2003, <b>28(12)</b> :1290-1299.
44.	Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability.
	Psychological bulletin 1979,86(2):420-428.
45.	Altay T, Gunal I, Ozturk H: Local injection treatment for lateral epicondylitis.
	ClinOrthopRelat Res 2002,(398):127-130.
46.	Croisier JL, Foidart-Dessalle M, Tinant F, Crielaard JM, Forthomme B: An isokinetic
	eccentric programme for the management of chronic lateral epicondylar tendinopathy
	Br J Sports Med 2007,41(4):269-275.
47.	Dogramaci Y, Kalaci A, Savas N, Duman IG, Yanat AN: Treatment of lateral
	epicondilitis using three different local injection modalities: A randomized prospective
	clinical trial. Archives of Orthopaedic and Trauma Surgery 2009, 129(10): 1409-1414.

48.	Paungmali A, O'Leary S, Souvlis T, Vicenzino B: Hypoalgesic and
	sympathoexcitatory effects of mobilization with movement for lateral epicondylalgia.
	<i>PhysTher</i> 2003, <b>83(4)</b> :374-383.
49.	Saartok T, Eriksson E: Randomized trial of oral naproxen or local injection of
	betamethasone in lateral epicondylitis of the humerus. Orthopedics 1986,9:191-194.
50.	Vicenzino B, Paungmali A, Buratowski S, Wright A: Specific manipulative therapy
	treatment for chronic lateral epicondylalgia produces uniquely characteristic
	hypoalgesia. Manual Therapy 2001,6(4):205-212.
51.	Viswas R, Ramachandran R, Korde Anantkumar P: Comparison of effectiveness of
	supervised exercise program and Cyriax physiotherapy in patients with tennis elbow
	(lateral epicondylitis): a randomized clinical trial. TheScientificWorldJournal
	2012, <b>012</b> :939645.
52.	Neyeloff JL, Fuchs SC, Moreira LB: Meta-analyses and Forest plots using a microsoft
	excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC
	research notes 2012,5:52.
53.	Cook JL, Purdam CR: Is tendon pathology a continuum? A pathology model to
	explain the clinical presentation of load-induced tendinopathy. Br J Sports Med
	2009,43(6):409-416.
54.	Haahr JP, Andersen JH: Prognostic factors in lateral epicondylitis: a randomized trial
	with one-year follow-up in 266 new cases treated with minimal occupational
	intervention or the usual approach in general practice. Rheumatology (Oxford)
	2003, <b>42(10)</b> :1216-1225.

55. Gaujoux-Viala C, Dougados M, Gossec L: Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2009,68(12):1843-1849.

## **FIGURES AND TABLES**

uploaded as web only data:

 Table 1: Demographics, treatments and outcome measures in the ten included studies

 Table 2: Quality rating of included studies by assessing internal and external validity with the PEDro scale

 Table 3: Effect size of improvement rate, reduction in pain and increase in grip

 strength for corticosteroid injection

 Table 4: Effect size of treatment effects for non-electrotherapeutic physiotherapy

Figure 1: Outline of the selection process

Figure 2: Forest-plot of effect sizes for corticosteroid injection

Figure 3: Forest-plot of effect sizes for non-electrotherapeutic physiotherapy

## PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page a					
TITLE								
Title	1	Identify the report as a systematic review, meta-analysis, or both.	in title					
ABSTRACT	•	·						
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	in abstract					
INTRODUCTION		·						
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5					
Objectives       4       Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).       6								
METHODS								
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-					
Eligibility criteria	criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.							
Information sources								
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8					
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-8					
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8-9					
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8-9					
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	12					
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-10					
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	8-10					

Page 29 of 38



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	17
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	na
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10, Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10-12, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12, Table 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13-15, table 3,4 figure 2,3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13-15. table 3,4 figure 2,3
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10,12,17
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	na
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	15-16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18-19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	20




From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

. A Group (2009). Preferred Rey. Page 2 c.

Protected by comparing and any technologies to technologies with a full and the second as.


Erasmushogeschool AT-L23 Inemited as 7202.51 (% M or monopological and the form of t


## Figure 1: Outline of the selection process





Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Figure 2. Forest-plot of effect sizes for corticosteroid injection









1: Corticosteroid injection (CSI) vs no intervention or NSAIDs

2: CSI vs lidocaine injection

3: CSI, excercise and stretching vs excersise and stretching. The values for Newcomer are given as change in pain and change in pain free grip strength. 

1 2 2	Figure 3. F	orest	-plot of e	ffect siz	es for	non-e	electrot	herap	eutic p	hysio	therap	y									
3 4 5	Manipulation Overall impro Author		nt RR (95% C		vours t		nt		Inte	ermedia	te term	(26 we	eks)				Long te	erm (52 v	veeks)		
6 7 8 9	Bisset Coombes <b>Pooled</b> NB different axis										-		-				_				
10 11 12	Pain SMD (95	0,00 % CI) -	2,00 4,00 negative va			10,00 1 ment	2,00	0,00	0,20	0,40 (	),60 0,8	0 1,0	0 1,20	1,40	0,00	0,50	)	1,00	1,	50	2,00
13 14	Author Bisset		Sho	rt term (4-	-12 wee	eks)	-		Inte	ermedia	te term	(26 we	eks)		-		Long te	erm (52 \	veeks)		
15 16	Coombes Pooled			-							_	 ◆ <del> </del>						_		-	
17 18 19		-2,00	-1,50 -1,0	0 -0,50	0,00	0,50	1,00	-2,00	-1,50	-1,00	-0,50	0,00	0,50	1,00	-2,00	-1,50	-1,00	-0,50	0,00	0,50	1,00
20 21	Pain free grip Author	streng		ected/ una rt term (4-			1D (95%)	- positiv			treatme te term		eks)				Long te	erm (52 v	veeks)		
22 23	Bisset Coombes			-		•		_				-				-			-		
24 25		-0,60	-0,10	0,4	40	0,90		-0,60	-0,:	10	0,40		0,90		-0,60	-0,	10	0,40		0,90	
26 27 28	Exercise vs no DASH score (			mplaints,	negativ	ve value	favours t	reatme	nt) SMD	(95%)											
29 30	Peterson		Sho	rt term (4-	-12 wee	eks) _															
31 32		-1,00	-0,50	0,00	0	0,50	1,00														
33 34 35	Pain on maxii	num v		ntraction S rt term (4-			negative	value fa	ivours tre	eatmen	:										
36 37	Peterson			-	_																
38 39	Pain on maxii	-1,00 num n	-0,50 nuscular elo	0,00 ngation SN		0,50 % Cl) - ni	1,00 egative va		ours trea	atment											
40 41	Peterson			rt term (4-																	
42 43 44		-1,00	-0,50	0,00		0,50	1,00														
45 46	Eccentric exc DASH score (		100 most co		negativ		favours t	reatme	nt) SMD	(95%)											
47 48 49	M-Silvestrini				12 wee																
50 51		1,00	-0,50	0,00		0,50	1,00														
52 53	Pain SMD (95	% CI) -		lue favour rt term (4-																	
54 55 56	M-Silvestrini	-1,00	-0,50	0,00	0	0,50	1,0	0													
56 57 58	Pain free grip		th affected		(95%)		2,0														
59 60	M-Silvestrini																				
		-1,00	-0,50	0,00		0,50	1,00														

			<mark>g vs stretchir</mark>		wours treat	ment) SMD (95%)					
DASITSCOLE	(0-100, 10		erm (4-12 we								
M-Silvestrin	ni										
	-1,00	-0,50	0,00	0,50	1,00						
Pain SMD (9	95% Cl) - ne		favours treat								
		Short te	erm (4-12 we	eks)							
M-Silvestrin	1i 										
	-1,00	-0,50	0,00	0,50	1,00						
Pain free gri	ip strength	affected arm Short te	n SMD (95%) erm (4-12 we	eks)							
M-Silvestrin	1i —										
	-1,00	-0,50	0,00	0,50	1,00						
Eccentric ex						d, elbow support)					
Improveme	nt/success		- RR>1 favour erm (4-12 we		nt	Intermediate term (26 weeks)		Lon	g term (52 we	eks)	
Selvanetti											
							0,00	50,00	100,00	150,00	200,00
Pain on Ko-	scale (larg	er value mea	ns less pain) !	SMD (95%)	CI)		.,	,	,	,	
			erm (4-12 we			Intermediate term (26 weeks)		Lon	g term (52 we	eks)	
Selvanetti									_		
	0,00 1	.,00 2,00	3,00 4,0	0 5,00	6,00		0,00	1,00 2,00	3,00 4,	00 5,00	6,00
Grip strengt	th on Ko-sc		ilue means gr erm (4-12 we		ngth) SMD (9	95%) Intermediate term (26 weeks)		Lon	g term (52 we	eks)	
Selvanetti	1										
	0,00	1,00 2,0	00 3,00	4,00	5,00		0,00	1,00	2,00 3,00	4,00	5,00
	0,00	1,00 2,0	50 5,00	4,00	3,00		0,00	1,00	2,00 3,00	4,00	3,00

#### Table 1: Demographics, treatments and outcome measures in the eleven included studies

e 35 of 38 Table 1: Demogi	raphics, trea	tments and or	utcome measures in th	BMJ Open ne eleven included studies		4 by copyright ht. 2000 (argenta)	
Study and year setting and sample size	Women (percentages)	Age (mean if not otherwise stated)	Duration of complaints (weeks)	Treatment groups	Control group	Ont 2 Outcome measures (excerpts)	Follow (weeks)
Bisset et al. 2006 Outpatient clinic n=198	35	47,6 (SD 7.8)	22 (median) (IQR: 12-42)	1: 10 mg triamcinolone and 1 ml lidocaine against the most painful point repeated after 2weeks     Elbow manipulation (manipulation with mowement) and excercise 8 sessions of 30 minutes duration during a 6 week period and home exercise	Information, wait-and-see	Piprovežent on 6-point Likert-scale Pini freegrip strength (PFGS) Sessesse verity on VAS-scale Bia on QSS Pini on QSS Pini on QSS	52
Coombes et al. 2013 Community setting n=165	38	49.7 (SD 8.1)	16 (median) (IQR 10-26)	One injection of 1 ml triamcinolone 10 ml/ml and     1 ml lignocaine 1% against site of greatest palpable tenderness     at the common extensor origin     Elbow manipulation (manipulation with mowement) and excercise     8 sessions of 30 minutes duration     during a 8 week period and home exercise     One injection of triamcinolone followed by 8 sessions of     elbow manipulation and excersie, home excercise for 8 weeks         (not considered in this review)	Placebo injection 0.5 ml 0.9 % isotonic saline	EproveDation 6-point Likert-scale Serie year Securrence Bain on @S STEE Destionnaire 11 ErroGG-5D quality of life score TroE Eras mus ted to 1	52
Hay et al. 1999 General practice n=164	Group 1: 41 (Group 2: 53) Control: 48	Age ≥ 45: (percentages) Group 1: 70 (Group 2: 68) Control: 38	9 (mean) Percentage with pain >3 months: Group 1: 36 (Group 2: 25) Control: 31	One injection of methylprednisolone 20 mg and 0.5 ml 1% lignocaine towards tender spot     Naproxen po 500 mg bid for 2 weeks (not considered in this review)	Placebo tablets	O     D       March Dependent on 5-point Likert-scale       March Dependent Likert-scale       March Dependent Likert-scale       March Dependent Likert-scale       March Dependent Dependent Likert-scale       Disagnitic Duestionnaire	52
Price et al. <b>1991</b> Outpatient clinic n=88	Group 1: 48 Group 2: 43 Control: 38	Group 1: 47 Group 2: 47 Control: 46 <i>(median)</i>	Group 1: 20 (6-150) Group 2: 36 (6-154) Control: 16 (6-150) (median and range)	Hydrocortisone 25 mg and 1% lidocaine against tender point (2 ml fluid) (55% received 2 injections)     Triamcinolone 10 mg and 1% lidocaine (30% received 2 injections)	2 ml 1% lidocaine against tender point	Alin on AS moderness score Main-wetthed grip strength n A G	24
Smidt et al. 2002 General practice n=185	Group 1: 55 (Group 2: 44) Control: 53	Group 1: 47 (Group 2: 48) Control: 46 <i>(median)</i>	Group 1: 11 (8-16) (Group 2: 11 (8-21)) Control: 11 (8-21) (median and IQR)	1: 10 mg triamcinolone and 1 ml lidocain againt all tender points up to 3 injections     2: One group reveived physiotherapy with ultrasound (not considered in this review)	Wait-and-see (some were prescribed naproxen po 1000 mg daily)	Provement on 6-point Likert scale Severity of complaint on scale Direction arises GS Baximum grip strength (MGS) Bessue Qain measurements Stisfacton with treatment	52
Toker et al. 2008 Outpatient clinic n=21	43	45 (range 19-72)	not stated	One injection of 1 ml metylprednisolon and 1 ml prilocain with oral diklofenac 3 tablets (dose not stated) and etofenamat topically	Oral diklofenac 3 tablets (dose not stated) and etofenamat topically	Proving abscense of pain Byscence of pain on palpation Wer latest epicondyle and on Bymethic dorsification of wrist Din score	4
Lindenhovius et al. 2008 Outpatient clinic n=64	Treatment: 63 Control: 60	Treatment: 50 +/- 8 Control: 51+/- 10	Treatment: 12 +/- 4 (2-20) Control: 8 +/- 4 (1-20)	4 mg dexamethasone and 10 mg lidocaine (2 ml fluid) against the most tender spot, fanning of the needle. One injection - but 6 of 64 got 2 injections.	10 mg lidocain, 2 ml fluid total	ASH questionnaire * Pain on VAS Orip strength	26
Newcomer et al. 2001 Outpatient clinic n=39	51	Treatment: 46.0 +/- 7.0 Control: 44.6+/- 7.6	Treatment: 3.2 (mean) SD 0.8 Control: 3.4 (mean) SD 0.9	One injection of 5 ml 4:10.25% bupivacaine and 6 mg/ml betamethasone against tender point. Home excercises consisting of ice massage, wrist stretching and progressive eccentric and concentric exercises	Placeboinjection of 5 ml bupivacaine Home excercises consisting of ice massage, wrist stretching and progressive eccentric and concentric exercises	ASH questionnaire * ASH questionnaire * Asin on AS Grip strength Doin on AS inctional pain questionnaire GFGS at and 8 weeks) ES. 20	26
<b>M-Silvestrini et al. 2005</b> Outpatient clinic n=94	47	45,5 +/- 7.7	more than 12	<ol> <li>Concentric strengthening 3x10 repetitions once daily and wrist stretching twice daily for 6 weeks</li> <li>Eccentric strengthening 3x10 repetitions once daily and wrist stretching twice daily for 6 weeks</li> </ol>	Wrist stretching twice daily for 6 weeks	PFGS Pain on VAS PRFEQ Lestionnaire† Patient's fog of training DASH agestionnaire *	6
Peterson et al. 2011 General practice n=81	42	48	Treatment: 107 Control: 96	Three-month daily exercise regime performed at home with progressively increasing load on the extensor muscles	Information, wait-and-see	Pain on the Source of the Sour	12 2r
Selvanetti et al. 2003 Setting not stated n=62	Treatment: 45 Control: 48	Treatment: 41,3 Control: 40,5	Treatment: 28 (8-40) Control: 29 (12-44)	4 weeks home-exercise after instruction from physiotherapist consisting of stretching and eccentric excercise Counseling and use of elbow support	Sham ultrasound 20 sessions Counseling and use of elbow support	Ko scoring system (includes clench test, Thomsen est and pain). Verhaarstpring system on global improvemu Subjecti Mimprovement VAS scale (0-100)	44 (24-56) ent

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### Table 2: Quality rating of studies by assessing internal and external validity with the PEDro scale

2         biplets were nameding shouldes to grapps         1	ubject         version         1 <th1< th="">         1         <th1< th="">         1         <th1< th=""><th></th><th></th><th></th><th></th><th></th><th>BMJ O</th><th>)pen</th><th></th><th></th><th>دة/bmjopen-2013-003564 o by copyright, includin∯t ⊛</th><th></th><th></th><th></th><th></th></th1<></th1<></th1<>						BMJ O	)pen			دة/bmjopen-2013-003564 o by copyright, includin∯t ⊛				
2         subjects were induced to groups         1 <th1< th="">         1         <th1< th="">         1         <th1< th="">         1         <th1<< th=""><th>ublest were inform y allocated to groups 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</th><th>ble 2: Quality rating of studies by as</th><th>sessing in</th><th>ternal and</th><th>external v</th><th>alidity witl</th><th>h the PEDr</th><th></th><th></th><th></th><th>13-0035 , includi</th><th></th><th></th><th></th><th></th></th1<<></th1<></th1<></th1<>	ublest were inform y allocated to groups 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ble 2: Quality rating of studies by as	sessing in	ternal and	external v	alidity witl	h the PEDr				13-0035 , includi				
2 solection we canoline and the statement of the statemen	ublest were inform y allocated to groups 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Bisset	Coombes	Нау	Price	Smidt		Lindenhovius	Newcomer		Peterson	Selvanetti	Kochar	Tonks
3 allocation was concared       1       1       1       0       1       0       1       0       1       0         4 model important proposition floators       0       0       0       1       <	Libration         1         1         1         1         0         1         0         1         0         1         0         1         1         1         1         0         1								1	1			1	1	1
image         image <th< td=""><td>Interval         I&lt;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td></th<>	Interval         I<														1
bit mere was binding of all subjects         0         0         1 <th1< th=""> <th1< th="">         1</th1<></th1<>	Unter was binding of all subjects         0         0         0         1         1         1         1         1         0         1         1         1         1         1         1         0         1         0	the groups were similar at baseline regarding the				-					se				0
here was under or all integers with administered 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0	Under data bases on who measured at the target who administered         0         0         0         0         1         1         1         1         1         1         1         0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td><u> </u></td> <td>1</td> <td></td> <td></td> <td></td>								1		<u> </u>	1			
Index summing of all relations were addinged         0         0         0         1         1         1         1         0 <td>Under data bases on who measured at the target who administered         0         0         0         0         1         1         1         1         1         1         1         0<td></td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td></td>	Under data bases on who measured at the target who administered         0         0         0         0         1         1         1         1         1         1         1         0 <td></td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td> <td></td> <td>0</td> <td>0</td> <td>0</td> <td>0</td>		0	0	0	1	0	0	1	1		0	0	0	0
to tradit the results of the theorem one stands of the traditional of	on treat       1<		0	0	0	0	0	0	1	1	äπč		0	0	0
ib breat/ ib presult       1	on treat       1<		U	0	U	U	U	U	1	1		U	U		
in trait         in trait         i	on treat       1<		1	1	1	1	1	0	1	0	d in 20	0	0	0	0
to tradit         1	on treat       1<	measures of at least one key outcome were obtained						-							
b track         1 </td <td>on treat       1&lt;</td> <td>from more than 85% of the subjects initially allocated</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td>0</td> <td>0</td>	on treat       1<	from more than 85% of the subjects initially allocated										1		0	0
to trail to be result of between group statistical comparisons in a similar technology of the table of the result of both early of the table one key outcome in the study provides both point measures and in the study point and states are study point at the study poi	on treat       1<	to groups	1		1	1	1	1	0	1	<u> </u>	1	1		
to best         1 </td <td>on treat       1&lt;</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td><u> </u></td> <td></td> <td></td> <td></td> <td></td>	on treat       1<										<u> </u>				
in trait         in trait         i	on treat       1<										an se an			0	-
in trait         in trait         i	on treat       1<										요양등			U	0
the study provides both point measures and measures of vanishing of a rank of the study new study of vanishing of a rank of the study new study	he study provides both point measures and measures of variability for at least one key outcome measures of variability for at least one key outcome Sum orderies 2 to 11, maximum score is 10)		1	1		4	4	4	4	4	ದ್ಲೆ ರ ಶ್ವ	4	4		
In study provides both point measures and measures of variability for a task one key outcome is 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	he study provides both point measures and measures of variability for at least one key outcome measures of variability for at least one key outcome Sum orderies 2 to 11, maximum score is 10)		I			1	1	1	1	I	<u> </u>	. 1	1		
the study provides both point measures and measures of variability for italisations key outcome          1 <t< td=""><td>he study provides both point measures and measures of variability for at least one key outcome measures of variability for at least one key outcome Sum orderies 2 to 11, maximum score is 10)</td><td>are reported for at least one key outcome</td><td>1</td><td>1</td><td>1</td><td></td><td>1</td><td>1</td><td>1</td><td>1</td><td>1. ď</td><td>· 1</td><td>1</td><td>1</td><td>1</td></t<>	he study provides both point measures and measures of variability for at least one key outcome measures of variability for at least one key outcome Sum orderies 2 to 11, maximum score is 10)	are reported for at least one key outcome	1	1	1		1	1	1	1	1. ď	· 1	1	1	1
Al training, and similar technologies.	Al training, and similar technologies.				· · ·		•		1		₹	· · ·			
Al training, and similar technologies.	Al training, and similar technologies.		1	1	1	1	1	1	1	1	<u>p</u> o	1	1	1	1
Al training, and similar technologies.	Al training, and similar technologies.	Total PEDro score	-	8	8	8	8	A	9		ੜੋਂ ∃	7	7	4	4
Al training, and similar technologies.	Al training, and similar technologies.		v		v	5	, in the second s		5	5	ê <mark>2</mark>	· ·	,		EXLUD
Department	GEZ-LI										2025 es.				
	F		_								-				

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		Short term 4-12 weeks	Intermediate term 26 weeks	Long term 52 weeks
Overall impr	ovement RR (95%	6 CI) RR>1 favours tr	eatment	
Cortic	costeroid injection (C	CSI) vs no intervention o	r NSAIDs	
	Bisset	2.94 (1.90 to 4.45)*	0.55 (0.41 to 0.73)*	0.75 (0.62 to 0.90)*
	Coombes	7.32 (2.83 to 18.94)*	0.68 (0.50 to 0.92)*	0.91 (0.77 to 1.06)
	Hay Smidt	1.60 (1.18 to 2.17)* 2.86 (1.96 to 4.16)*	0.77 (0.60 to 0.98)*	1.07 (0.88 to 1.30) 0.84 (0.68 to 1.02)
	Toker	2.27 (1.04 to 4.97)*	-	-
	Pooled	-	0.66 (0.53 to 0.81)*	0.87 (0.73 to 1.04)
	Heterogeneity	>65%	p=0.21 l <sup>2</sup> =35%	p=0.07 l <sup>2</sup> =58%
CSI vs	lidocaine injection			
051 15	Lindenhovius	-	-	-
	Price	-	-	-
	vcercise and stretch	ing vs excersise and stre	tching	
C31, E	Newcomer	-	-	-
Pain (negativ	ve value favours t	reatment) SMD (95%	% CI)	
CSLVS	no intervention or l			
651 75	Bisset	-1.43 (-1.83 to -1.04)*	0.40 (0.04 to 0.76)*	0.27 (-0.08 to 0.62)
	Coombes	-2.14 (-2.68 to -1.60)*	0.16 (-0.28 to 0.59)	0.08 (-0.35 to 0.52)
	Нау	-1.05 (-1.45 to -0.66)*	0.42 (0.04 to 0.80)*	1.35 (0.94 to 1.76)*
	Smidt	-1.49 -(1.89 to -1.08)*	0.27 (-0.09 to 0.63)	0.15 (-0.20 to 0.51)
	Toker Pooled	-1.14 (-2.07 to -0.22)* -1.43 (-1.64 to -1.23)*	- 0.32 (0.13 to 0.51)*	-
	Heterogeneity	$p=0.032 l^2=62\%$	$p=0.79 l^2=0\%$	- >65%
	<u> </u>			
CSI vs	lidocaine injection Lindenhovius	-0.25 (-0.74 to 0.24)	0.27 (-0.30 to 0.84)	
	Price 1	-1.06 (-1.63 to -0.49)*	3.13 (2.31 to 3.95)*	-
	Price 2	-3.37 (-4.20 to -2.54)*	1.55 (0.93 to 2.17)*	-
	Pooled	-	-	-
	Heterogeneity	>65%	>65%	-
All above	pooled	-	-	
Heterogen	eity	>65%	>65%	
CSL e	xcercise and stretch	ing vs excersise and stre	tching	
coi, c	Newcomer <sup>+</sup>	0.16 (-0.49 to 0.81)	-0.37 (-1.04 to 0.30)	_
		0.10 ( 0.15 to 0.01)		
Maximum gr	ip strength (posit	tive value favours tre	eatment) SMD (95%	CI)
<b>C</b> (1)				
CSIVS	no intervention or I Bisset	-	-	<u>-</u>
	Coombes	-	-	-
	Нау	-	-	-
	Smidt	-1.42 (-1.82 to -1.03)*	-0.38 (-0.74 to -0.02)*	-0.36 (-0.72 to 0.002
	Toker	-	-	-
	no pooling	-	-	-
CSI vs	lidocaine injection			
	Lindenhovius	-0.19 (-0.68 to 0.30)	0.07 (-0.50 to 0.64)	-
	Price 1 Brice 2	-0.06 (-0.59 to 0.48)		-
	Price 2 Pooled	2.31 (1.62 to 3.00)*	-0.86 (-1.44 to -0.29)*	-
	Heterogeneity	- >65%	- >65%	
	pooled	-	-0.48 (-0.73 to -0.24)*	-
All above				
<b>All above</b> Heterogen		>65%	p=0.04 I <sup>2</sup> =64%	-
Heterogen	eity	>65% ing vs excersise and stre		-

Price 1: hydrocortisone vs. lidocaine Price 2: triamcinolone vs lidocaine

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Table 4. Effect sizes of treatment effects for non-electrotherapeutic
---

	Short term	Intermediate term	Long term
	4-12 weeks	26 weeks	52 weeks
nipulation and exercise	vs no intervention		
Overall improvement	RR (relative risk) (95% Cl	) - RR>1 favours treatn	nent
Bisset	2.44 (1.54 to 3.85)*	0.94 (0.78 to 1.12)	1.04 (0.93 to 1.15)
Coombes	4.00 (1.46 to 10.94)*	1.06 (0.89 to 1.28)	1.08 (0.99 to 1.18)
Pooled	2.75 (2.09 to 3.62)*	0.99 (0.75 to 1.30)	1.05 (0.75 to 1.49)
Heterogeneity	p=0.37 l <sup>2</sup> =0%	p=0.33 l <sup>2</sup> =0%	p=0.57 l <sup>2</sup> =0%
Pain SMD (standardis	ed mean difference) (959	% CI) - negative value fa	avours treatment
Bisset	-0.63 (-0.99 to -0.27)*	-0.25 (-0.62 to 0.11)	-0.38 (-0.74 to -0.03)
Coombes	-1.27 (-1.74 to -0.79)*	0.00 (-0.44 to 0.44)	0.00 (-0.44 to 0.44)
Pooled	-	-0.15 (-0.43 to 0.13)	-0.23 (-0.51 to 0.04)
Heterogeneity	p>65%	p=0.39 I <sup>2</sup> =0%	p=0.18 l <sup>2</sup> =45%
Pain free grip strengt	h ratio affected/ unaffect	ed arm SMD (95%)	
Bisset	0.76 (0.39 to 1.13)*	0.20 (-0.47 to 0.56)	0.17 (-0.18 to 0.52)
Coombes		-	-
ercise vs no intervention			
	00 most complaints, nega	ative value favours trea	atment) SMD (95%)
Peterson	-0.03 (-0.47 to 0.40)	-	-
Pain on maximum vol	luntary contraction SMD	(95% CI) - negative valu	ue favours treatment
Peterson	-0.30 (-0.74 to 0.14)	-	-
Pain on maximum mu	uscular elongation SMD (S	95% CI) - negative valu	e favours treatment
Peterson	-0.24 (-0.68 to 0.19)	-	-
entric excercise and stre	tching vs stretching		
DASH score (0-100, 10	00 most complaints, nega	ative value favours trea	atment) SMD (95%)
M-Silvestrini	-0.07 (-0.46 to 0.60)	-	-
	agativa valua favoura tra	atmost	
	negative value favours tre	atment	
Pain SMD (95% Cl) - n <b>M-Silvestrini</b>	egative value favours tre -0.04 (-0.57 to 0.49)	atment -	Q
M-Silvestrini	-0.04 (-0.57 to 0.49)	-	Q.
M-Silvestrini Pain free grip strengt	-0.04 (-0.57 to 0.49) h affected arm SMD (95%	-	Q4
M-Silvestrini	-0.04 (-0.57 to 0.49)	-	C Z
M-Silvestrini Pain free grip strengt	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27)	-	Q Z O
M-Silvestrini Pain free grip strengti M-Silvestrini ncentric excercise and str	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching	- 6) -	- -
M-Silvestrini Pain free grip strength M-Silvestrini ncentric excercise and str DASH score (0-100, 10	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega	- 6) -	- - atment) SMD (95%)
M-Silvestrini Pain free grip strengti M-Silvestrini ncentric excercise and str	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching	- 6) -	- - atment) SMD (95%)
M-Silvestrini Pain free grip strengt M-Silvestrini ncentric excercise and str DASH score (0-100, 10 M-Silvestrini	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68)	- 6) - ative value favours trea -	- atment) SMD (95%)
M-Silvestrini Pain free grip strengt M-Silvestrini ncentric excercise and str DASH score (0-100, 10 M-Silvestrini	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) regative value favours tre	- 6) - ative value favours trea -	- atment) SMD (95%) -
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68)	- 6) - ative value favours trea -	- atment) SMD (95%) -
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95)	- ative value favours trea - atment -	- atment) SMD (95%) -
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) regative value favours tre	- ative value favours trea - atment -	- atment) SMD (95%) - -
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strengt M-Silvestrini	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) regative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20)	- ative value favours trea - vatment - 6) -	-
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strengt	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) regative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20)	- ative value favours trea - vatment - 6) -	-
M-Silvestrini Pain free grip strength M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strength M-Silvestrini entric excercise and stre	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20) tching vs no intervention	- ative value favours trea - eatment - 6) - n (sham ultrasound, elt	-
M-Silvestrini Pain free grip strength M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strength M-Silvestrini entric excercise and stre	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) regative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20)	- ative value favours trea - eatment - 6) - n (sham ultrasound, elt	-
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strengt M-Silvestrini entric excercise and stree Overall improvement	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20) tching vs no intervention	- ative value favours trea - eatment - 6) - n (sham ultrasound, elt	- - Dow support)
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strengt M-Silvestrini entric excercise and stree Overall improvement Selvanetti	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20) tching vs no intervention	- ative value favours trea ative value favours trea ative value favours trea ative value favours trea ative value favours treat ative value favours	- - pow support)
M-Silvestrini Pain free grip strengt M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strengt M-Silvestrini entric excercise and stree Overall improvement Selvanetti	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20) tching vs no intervention	- ative value favours trea ative value favours trea ative value favours trea ative value favours trea ative value favours treat ative value favours	- - Dow support)
M-Silvestrini Pain free grip strength M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strength M-Silvestrini entric excercise and stree Overall improvement Selvanetti Pain on Ko-scale (larg	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20) tching vs no intervention RR (95% CI) - RR>1 favou	- ative value favours trea ative value favours trea ative value favours trea ative value favours trea ative value favours treat ative value favours	- - pow support) 23.39 (3.38 to 161.70
M-Silvestrini Pain free grip strength M-Silvestrini DASH score (0-100, 10 M-Silvestrini Pain SMD (95% Cl) - n M-Silvestrini Pain free grip strength M-Silvestrini entric excercise and stree Overall improvement Selvanetti Pain on Ko-scale (larg Selvanetti	-0.04 (-0.57 to 0.49) h affected arm SMD (95% -0.26 (-0.79 to 0.27) retching vs stretching 00 most complaints, nega 0.14 (-0.39 to 0.68) negative value favours tre 0.41 (-0.13 to 0.95) h affected arm SMD (95% -0.34 (-0.88 to 0.20) tching vs no intervention RR (95% CI) - RR>1 favou	- ative value favours trea ative value favours trea atment - atment - (sham ultrasound, elb urs treatment - ) SMD (95% CI)	- - - 23.39 (3.38 to 161.70 4.65 (3.68 to 5.63)*

\*: statistically significant (p<0.05)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



# Treating lateral epicondylitis with corticosteroid injections or non-electrotherapeutical physiotherapy: a systematic review

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-003564.R1
Article Type:	Research
Date Submitted by the Author:	27-Aug-2013
Complete List of Authors:	Olaussen, Morten; University of Oslo, Department of General Practice Holmedal, Oeystein; University of Oslo, Department of General Practice Lindbaek, Morten; University of Oslo, Department of General Practice Brage, Soeren; University of Oslo, Department of Community Health Solvang, Hiroko; University of Oslo, Department of General Practice
<b>Primary Subject Heading</b> :	Sports and exercise medicine
Secondary Subject Heading:	General practice / Family practice
Keywords:	SPORTS MEDICINE, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, Elbow & shoulder < ORTHOPAEDIC & TRAUMA SURGERY



# Abstract

# Objectives

To evaluate the current evidence for the efficacy of corticosteroid injection and non-

electrotherapeutic physiotherapy compared with control for treating lateral epicondylitis.

# Design

Systematic review.

# Setting

n/a

# Participants

We searched five databases in September 2012 for randomized, controlled studies with a minimum quality rating. Of 640 studies retrieved, eleven were included, representing 1161 patients of both sexes and all ages.

# Interventions

Corticosteroid injection and non-electrotherapeutic physiotherapy.

# **Outcome measures**

Relative risk (RR) or standardised mean difference (SMD) for overall improvement, pain and grip strength at 4 to 12, 26 and 52 weeks follow-up.

# Results

Corticosteroid injection gave a short-term reduction in pain vs no intervention or NSAIDs (SMD -1.43, 95% CI -1.64 to -1.23). At intermediate follow-up, we found an increase in pain (SMD 0.32, 95% CI 0.13 to 0.51), reduction in grip-strength (SMD -0.48, 95% CI -0.73 to -

0.24), and negative effect on overall improvement effect (RR 0.66 (0.53 to 0.81). For corticosteroid injection vs lidocaine injection, evidence was conflicting. At long-term follow up, there was no difference on overall improvement and grip strength, with conflicting evidence for pain. Manipulation and exercise vs no intervention showed beneficial effect at short-term follow-up (overall improvement RR 2.75, 95% CI 1.30 to 5.82), but no significant difference at intermediate or long-term. We found moderate evidence for a short- and long-term effect of eccentric exercise and stretching vs no intervention. For exercise vs no intervention and eccentric or concentric exercise and stretching vs stretching alone, we found moderate evidence of no short-term effect.

### Conclusions

Corticosteroid injections have a short-term beneficial effect on lateral epicondylitis, but a negative effect at intermediate term. Evidence on long-term effect is conflicting. Manipulation and exercise and exercise and stretching have a short-term effect, the latter also a long-term effect.

# **Trial registration**

None.

# **Article summary**

# Article focus

• What is the current evidence for the effect of treating lateral epicondylitis with corticosteroid injection or non-electrotherapeutic physiotherapy compared to control?

# Key Messages

- Corticosteroid injections have a short-term beneficial effect on lateral epicondylitis, but a negative effect at intermediate term. Evidence on long-term effect is conflicting.
- There is evidence for a short-term effect of manipulation and exercise and exercise and stretching, for the latter also on long-term.

# Strengths and limitations of this review

• We found overall few good quality studies on these treatments, making a metaanalysis possible only for a few studies and outcomes.

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# Introduction

Lateral epicondylitis of the elbow is a frequently encountered complaint in general practice with an incidence of 4 - 7 per 1000 per year [1-3]. It is characterised by pain and tenderness over the lateral humeral epicondyle and pain on resisted dorsiflexion and radial deviation of the wrist. It is usually a self-limiting condition, often resolving in 6 to 12 months regardless of treatment, but complaints may last up to 2 years or longer [4]. Due to considerable pain and discomfort, many patients need time off from work.

Most authors attribute the condition to a lesion in the short radial extensor muscle [1, 5]. A recent study has found evidence of reduced hyperaemia measured with spectral and colour Doppler in lateral epicondylitis treated with corticosteroid injection, suggesting evidence of an inflammatory component [6]. Others, finding little evidence of inflammation have proposed the term "lateral epicondylalgia" for the condition [7].

Most patients with lateral epicondylitis are treated in general practice, and although a large number of treatments are in use, there is no consensus on which treatments are most effective. The Cochrane Library has reviewed several treatments. For topical NSAIDs and NSAIDs taken orally, the conclusion is that both may have a short term effect [8]. For extracorporeal shockwave therapy, a review of nine studies including 1000 patients found this treatment to have no effect [9]. For acupuncture [10], deep friction massage [11], orthosis [12] and surgery [13] the reviews were inconclusive due to few and methodologically weak studies.

Four review articles have been published on the effect of corticosteroid injections [14-17]. They found a short-term effect of corticosteroid injection, but no proven long-term effect, and one review found evidence of a negative long-term effect [15]. However, some of the reviews included non-controlled studies [14, 16] and non-randomised studies [16]. In one

## **BMJ Open**

Five reviews of physiotherapeutic interventions show that there are few published studies on the effect of non-electrotherapeutic treatment, and many have methodological weaknesses [16, 18-21]. Bisset et al. [18] found evidence that manipulation and exercise had a short term effect. Four other reviews [16, 19-21] found short-term effects of mobilisation, manipulation and exercise. Three of these reviews included non-randomised or non-controlled studies [16, 19, 21]. Most previous systematic reviews have included electrotherapeutic physiotherapy such as ultrasound and extra-corporeal shockwave [14, 16, 20, 21].

Since there is no established, well-documented treatment to which new treatments can be compared, the use of a control group is important. The natural course of the condition, where most patients eventually recover regardless of intervention, makes this even more necessary. In a comparison of two different treatments, any effect found may only reflect this natural course of recovery unless the treatments prove better than a control group with no treatment.

It has been shown that systematic reviews which include studies with low scores on internal validity may over-estimate effect sizes, thus introducing a potential bias to the review [22]. There may also be a problem using rating scales with heterogeneous criteria, including i.e. criteria related to external validity, interpretation or ethical issues [22, 23].

To address these issues, a new systematic review on non-electrotherapeutic physiotherapy and corticosteroid injection seemed warranted. We wanted to include only randomised studies with a control group with no treatment or studies in which the groups only differed in regards to the investigated treatment. An established quality rating scale would be used. We also wanted to review the most current evidence on the efficacy of corticosteroid injection, since previous reviews have differing conclusions on long-term effect.

## Objective

The aim of this review was to assess the current evidence for the efficacy of corticosteroid injection and non-electrotherapeutical physiotherapy compared with control in patients with tennis elbow.

# Methods

We followed the recommendations of the Cochrane Collaboration [24] and the PRISMA Group [25] in the search and report of this systematic review.

# **Study selection**

We used the following inclusion criteria:

# Study type

Randomized, controlled trials assessing treatments for lateral epicondylitis or tennis elbow were eligible for inclusion. The studies had to have at least one treatment group and one control group. We defined a control group as a group receiving no treatment (a wait-and-see approach), common treatments with expected or known moderate effect (advice, rest, NSAIDs, pain-killers) or the same treatment as the experimental group with the exception of the investigated treatment.

# Participants

All age groups with a clinical diagnosis of lateral epicondylitis were included without restriction on gender.

# Treatments

We searched for studies investigating or comparing the efficacy of one of the following treatments: corticosteroid injection, non-electrotherapeutic physiotherapy including stretching, mobilisation, manipulation, massage, exercise or home training. Studies on splinting, ultrasound, shock wave and other electrotherapeutic modalities were excluded.

## Outcome measures and follow up

At least one validated, patient-centred outcome was necessary. This could include outcomes important to the patient such as pain, range of movement, grip strength, work status and relevant functional questionnaires. We included only studies done in a clinical setting with at least four-week follow-up of treatment effect. BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

# Study quality assessment

We used the 11-item PEDro scale to assess the quality of the studies included in the review. This rating system closely resembles the Cochrane Collaboration Scoring system [24] and is based on the Delphi list, developed for quality assessment of randomised controlled trials by Verhagen et al. [26]. It has been used in several previously published reviews [15, 18, 19]. The PEDro scale assesses the internal and external validity of a study by addressing the issues of eligibility criteria, randomisation, allocation, blinding, statistics and data reporting. The reliability of this scale has been confirmed by Maher et al in 2003 [27]. The maximum score is 10, since item number one on the scale (specified eligibility criteria) is not counted.

A minimum score of 5 out of 10 points (50%) was chosen to be necessary for inclusion in the review, as inclusion of lower quality studies in a systematic review may overestimate the treatment effect of interventions [28]. Ten studies were independently assessed

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

by two researchers (MO, ØH) [29-38] and three studies were rated by both researchers together [39-41]. The final decision on PEDro score was reached by consensus.

#### Search methods for identification of studies

#### Electronic searches

From October 2009 to January 2010, we searched the following databases for publications: Medline (Ovid and PubMed), EVSCO/Cinahl, Embase, Allied and Complimentary Medicine, The Physiotherapy Evidence Database (PEDro) and the Cochrane RCT register. The searches within each database were done without restrictions on dates or languages. We used free text, not MESH terms, in these searches, and the key terms used were "tennis elbow", "lateral epicondylitis", epicondylalgia, elbow, randomised, randomized, injection, corticosteroid, and physiotherapy. The Boolean operator AND was used to link diagnostic terms and treatment where applicable. An additional search was done in September 2012 to identify any recently published studies.

#### Searching other resources

Further search was done in the reference list of articles initially considered for review.

#### Selection of studies

The searches resulted in a number of studies potentially eligible for inclusion. Titles and abstracts were then read by two researchers independently (MO,  $\emptyset$ H) and potential studies were selected based on the inclusion criteria. The final decision on inclusion was made by consensus from reading the full-text documents.

#### Data extraction and statistical analysis

The included studies were read in full text and assessed by two independent researchers (MO,

ØH). One article, published in Italian, was translated by a professional bureau [41]. A

standardized set of data was extracted from each selected study and recorded using standardized forms. We calculated statistics using the statistical computing language R (www.r-project.org, The R Foundation for Statistical Computing, Vienna, Austria). We reported the results of the outcome measures for three different timings of follow-up, defined as short-term (four to 12 weeks after randomisation), intermediate term (six months after randomisation) and long-term (more than six months after randomisation). For dichotomous data, we calculated relative risk (RR) and 95% confidence intervals (CI) with the R-project library "epi.R", for continuous data the standardised mean difference (SMD) and 95% CI with the R-project library "compute.es". We pooled estimates when we found sufficient clinical and statistical homogeneity between trials using the I<sup>2</sup> statistic, defined as I<sup>2</sup> less than 65% [42].

Some studies did not report the mean, standard deviation or number of samples, which were necessary to calculate SMD. Additional calculations were then required. For Coombes [38], the median and the interquartile range (IQR) were given. We set the median as the mean value and the standard deviation was given by IQR/1.35 under the assumption of normal distribution. For Newcomer [33], the standard deviation was calculated by t-statistics obtained by the p-value and degrees of freedom. For Price [34], the t-statistics was obtained by the degrees of freedom and 95% probability. The standard deviation was estimated by the t-statistics, the mean value and upper/lower confidence intervals.

For overall improvement, a RR larger than 1 favoured treatment, and was statistically significant if the CI excluded 1. We defined the effect as large for values larger than 2 or less than 0.5, medium between 0.5 and 0.8 and between 1.25 and 2 and small for values between 0.8 and 1.0 and between 1.0 and 1.25.

For continuous data, a positive or negative SMD favoured treatment depending on the outcome measures, ie. for pain a negative SMD favoured treatment and for grip strength a

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

positive SMD favoured treatment. SMD was statistically significant if the CI excluded zero. We defined the effect as large for SMD more than 0.8, medium between 0.5 and 0.8 and small for values less than 0.5. For outcomes that could not be pooled, we graded the strength of the scientific evidence as strong (consistent findings in several high-quality randomised controlled studies), moderate (one high-quality randomised controlled study), conflicting (inconsistent finding between many studies) or no evidence [43].

# Inter-rater reliability

The inter-rater reliability for the individual PEDro scores was assessed by calculating the intra-class correlation coefficient [44]. The R-project library "psych" was used for this calculation. A substantial inter-rater reliability was found (intra-class correlation coefficient 0.69 (0.15-0.91), p<0.01).

# **Results**

The search retrieved an initial 839 hits, representing 640 individual articles. The further selection process is outlined in Figure 1. 623 articles were excluded based on title and abstract in a preliminary review. 17 articles [29-37, 39, 41, 45-50] were then assessed using the full-text documents. Three were found not to be randomised controlled trials [45-47], two had a PEDro quality rating below 50% (Table 2) [37, 39] and three had a follow-up shorter than four weeks [48-50]. The additional search done in september 2012 retrieved two possible studies [40, 51], one of which was excluded for not having a control group [51]. A recently published study was also assessed [38] and a total of 11 studies were included in the final review [29-36, 38, 40, 41].

# **Included studies**

The characteristics and details of each study are given in Table 1. The included studies represented a total population of 1161 patients. Several studies had more than one treatment

## **BMJ Open**

The mean age of patients varied from 41 to 51 years and the female percentages varied from 35 to 63. There were large differences in duration of complaints at baseline between studies. Most had a duration of several weeks to months and only one stated a short duration [33]. Eight studies had control groups with no active treatment [29-31, 34-36, 38, 40], e.g. a wait-and-see group or NSAIDs. Two of these used lidocaine as a placebo injection [31, 34]. In the three other studies, the control and treatment groups both received similar active treatments, with the intervention group in addition receiving the treatment to be investigated [32, 33, 41].

Eight studies investigated corticosteroid injections, representing 925 patients [29-31, 33-36, 38]. Five different corticosteroids were used, with different dosages and injection techniques. The control groups received no active treatment in seven of the eight studies, in one study both the control and treatment group received additional exercise treatment [33]. Seven of the studies had a long-time follow up of 24 weeks or more [29-31, 33-35, 38].

There were few studies covering non-electrotherapeutic physiotherapy. We found five studies which could be included, representing 600 patients [29, 32, 38, 40, 41]. The treatment modalities investigated were manipulation and exercise [29, 38], concentric or eccentric exercises [32], exercise [40] and eccentric exercises with stretching [41]. Three studies had a control group with no active treatment [29, 38, 40], the other two had control groups that received stretching and orthosis respectively. Three studies [29, 38, 41] had a follow up of 24 weeks or more.

The most frequently used outcome measures were assessment of pain and grip strength. Six studies measured pain free grip strength with handheld dynamometers [29-33,

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

35]. Eight studies used a number of different questionnaires covering pain, function and disability [29-33, 35, 38, 40]. Nine studies assessed pain on a visual analogue scale or Likert-scale [29-34, 36, 38, 40], and six studies rated patient's assessment of improvement on graded scales [29, 30, 35, 36, 38, 41].

# Risk of bias in included studies

We addressed the issues of the quality of the included studies and completeness of reported data by rating them with the PEDro scale (Table 2). Most studies used a computerized randomisation schedule, and seven of the eleven studies used concealed allocation [29-31, 35, 38, 40, 41]. Baseline comparison was done in all studies, the dropout rate was below 15% in ten studies [29, 30, 32-36, 38, 40, 41] and intention to treat analysis was stated in all studies. There was between-group analysis of at least one outcome measure in all the studies, and both point-measures and variations of outcome measures were reported in all studies.

The use of blinding was more diverse among the studies. Blinding the subject for treatment is difficult for physiotherapeutic treatments, but the use of blinded assessors reduces the risk of bias. None of the studies on physiotherapy in our review had blinded subjects or therapists, but two used blinded assessors [29, 38]. This might give biased results in the studies covering physiotherapeutic treatments.

For the eight studies on corticosteroid injection, the number using blinding was larger. There was blinding of subjects in four studies [31, 33, 34, 38], of the treating doctor in two [31, 33] and of assessors in six studies [29-31, 34, 35, 38].

In several studies the control group received some form of treatment (although similar to the treatment group) [32-34, 36, 41]. In these studies, synergistic effects between the treatments cannot be ruled out. This makes the results more difficult to interpret. Two studies had a short follow up of four and six weeks [32, 36], which for a condition usually lasting

#### **BMJ Open**

several months, reduces the clinical implication of the results. Difference in duration of complaints at baseline also complicates comparison between studies.

#### **Effects of interventions**

#### Corticosteroid injection

The efficacy of corticosteroid injection for treating lateral epicondylitis was investigated in eight studies (Table 3 and Figure 2 [52]). For short-term follow up, heterogeneity between studies made pooling of outcomes only possible for pain. For corticosteroid injection vs no intervention or NSAIDs, we found strong evidence for a beneficial effect on overall improvement and a large positive effect on pain [29, 30, 35, 36, 38]. For grip strength, we found moderate evidence for a negative effect [35]. For corticosteroid injection vs lidocaine injection, evidence was conflicting for effect on pain, with two studies showing a large positive effect (Price et al. using hydrocortisone and triamcinolone) [34] and one showing no significant difference [31]. For maximum grip strength, the evidence was also conflicting, with one study showing a large positive effect of treatment (Price et al. using triamcinolone)[34], and two studies showing no statistical difference (Lindenhovius, Price et al. using hydrocortisone) [31, 34]. For corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found moderate evidence for no significant difference on pain and grip strength [33].

At intermediate follow-up, we found sufficient homogeneity to poole estimates for overall improvement [29, 30, 38] and pain [29, 30, 35, 38] for corticosteroid injection vs. no intervention or NSAIDs. For overall improvement this showed a medium negative effect and for pain a small negative effect. For maximum grip strength, pooling of corticosteroid injection vs no intervention, NSAIDS and lidocaine showed a small negative effect [31, 34, 35]. For corticosteroid injection vs lidocaine injection, pooling of estimates was not possible due to heterogeneity. For pain, two studies showed a large negative effect (Price et al. using

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

hydrocortisone and triamcinolone)[34], and one study showed no significant difference [31], thus the evidence was conflicting. For grip strength, the evidence was also conflicting, with the same two studies showing a large negative effect [34] and one showing no significant difference [31]. For corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found moderate evidence of no significant effect on pain [33].

At long-term follow-up, pooled estimates of overall improvement showed no difference in effect of corticosteroid injection vs no intervention or NSAIDs [29, 30, 35, 38]. For pain, heterogeneity prevented pooling and we found the evidence conflicting with one study showing a large negative effect [30], and three others showing no significant difference in effect [29, 35, 38]. For grip strength, we found moderate evidence of no significant difference [35]. For corticosteroid injection vs lidocaine injection and corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found no data on long-term effect.

# Physiotherapy

We included five studies (n=600) investigating non-electrotherapeutical physiotherapy, representing five different treatment modalities (Table 4 and Figure 3 [52]).

Two studies investigated the efficacy of manipulation and exercise vs. no intervention [29, 38]. At short-term, pooled estimates showed a large positive effect on overall improvement. For pain, pooling was not possible due to heterogeneity. We found strong evidence for a beneficial effect, for pain free grip strength we found moderate evidence for a beneficial effect. At intermediate-term, pooled estimates showed no difference between treatment and control for neither pain nor overall improvement. There was moderate evidence for no difference in pain free grip strength. At long-term, pooled estimates again showed no difference between treatment and control for neither pain nor overall improvement and we found moderate evidence for no difference in pain free grip strength. At long-term, pooled estimates again showed no difference between treatment and control for either pain or improvement and we found

#### **BMJ Open**

The efficacy of exercise vs no intervention was investigated in one study [40]. We found moderate evidence for no short-term difference in effect for outcomes on pain and DASH-score. There was no data on intermediate- or long-term effect.

For eccentric exercise and stretching vs stretching, investigated in one study [32], we found moderate evidence for no short-term treatment effect for outcomes on pain, pain-free grip strength and DASH-score. There was no data on intermediate- or long-term effect.

The same study also investigated the efficacy of concentric exercise and stretching vs stretching. We found moderate evidence for no short-term treatment effect for outcomes on pain, pain-free grip strength and DASH-score. There was no data on intermediate- or long-term effect.

Eccentric exercise and stretching vs no intervention was investigated in one study [41]. We found moderate evidence for a positive effect on pain and grip strength at short-term follow up. There was no data on efficacy at intermediate follow-up, but at long-term, we found moderate evidence of a positive effect on overall improvement, pain and grip strength.

# Discussion

# Summary of main results

This review found overall evidence for a short-term beneficial effect of corticosteroid injection. At intermediate follow-up, the evidence showed an overall negative effect. For corticosteroid injection vs lidocaine injection, we found the evidence to be conflicting. At long-term follow up, the evidence suggest no difference in effect on overall improvement and grip strength, but the evidence was conflicting for pain. For manipulation and exercise vs no intervention, we found an overall beneficial effect at short term, but no significant difference at intermediate or long-term follow-up. The evidence on exercise vs no intervention showed no differences at short-term follow up. For eccentric exercise and stretching vs stretching

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

alone, the evidence showed no short-term difference in effect. The same was found for concentric exercise and stretching vs stretching. The evidence on eccentric exercise and stretching vs no intervention showed a beneficial effect at short-term and long-term, while there was no data on intermediate follow-up.

For treating lateral epicondylitis, this review showed evidence for a short-term benefit of corticosteroid injection and manipulation with exercise. Eccentric exercise and stretching showed beneficial effect both at short- and long-term follow-up.

## Overall completeness and quality of the evidence

 There is a paucity of well-designed studies for determining the effect of nonelectrotherapeutic physiotherapy. The conclusions on the effect of these treatments are therefore limited. A comparison and review of several individual studies was only possible for one treatment modality, manipulation and exercise vs no intervention (Table 4).

We included eight studies treating a total of 925 patients with corticosteroid injections in our review. The conclusions for this treatment are more solid due to the larger number of studies, seven of which had long-term follow up. Due to differences in type of corticosteroids used, treatment regimes and outcome measures in the included studies, pooling of outcome measures was difficult. We found statistical heterogeneity for most outcomes, and pooling was only possible for a few of the outcomes and follow-ups. The long-term effect of corticosteroid injection showed conflicting results in the included studies. The large differences across the studies in duration of complaints at baseline, corticosteroids used in different dosages, and control group treatments may explain this.

The difference in duration of complaints at baseline complicates the interpretation and comparison of the results, since there might be different effects of the treatments on an epicondylitis of recent onset compared to one that has lasted several months. This is also reflected by Cook [53] who considered tendinopathy as a continuum with three stages and

### **BMJ Open**

different characteristics and presumably treatments for each stage. Haahr [54] found that high physical strain at work, work with manual tasks, high perceived stress at baseline and a high level of pain and dysfunction seem to predict an unfavourable outcome after one year. Thus any differences in baseline characteristic for these parameters might possibly influence between-group differences of outcome.

## Potential biases in the review process

The search process, selection of search terms and possible errors in reading and assessing the large number of articles represent a possible bias. Although we have searched several databases with a number of search terms, we may have missed some published studies. To reduce the risk of bias in the inclusion process, we used two reviewers who independently screened articles.

Our choice of inclusion criteria, especially the type of control or comparison treatment and the use of a cut-off quality score (PEDro), has important implications for the conclusions that can be drawn from this review. The efficacy of the treatments are here only compared with a control (no treatment) or to an underlying treatment that is common to both intervention groups, so no conclusion can be drawn on which of two different treatments is best.

To address the issue of publication bias, we searched two clinical trial registries: ClinicalTrial.gov (US National Institutes of Health) and Current Clinical Trials. We found no completed, unpublished studies on corticosteroid injection. Two completed studies on nonelectrotherapeutic physiotherapy were found. One from The United Kingdom completed in 2008 on manipulation with movement and one from Sweden completed in 2009 on eccentric training. We have found no published articles from these studies. Unpublished studies are not indexed in PubMed or other databases and older studies may have been conducted without

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

registration in a clinical trial registry, making it difficult to make an overall assessment of publication bias.

## Agreements and disagreements with other reviews

Our findings agree with earlier reviews [14, 16, 17, 55]. We found consistent evidence of a beneficial short-term effect of corticosteroid injections, but evidence on the long-term effect is still conflicting. Coombes et al. [15] found in their review that corticosteroid injections have a worse outcome in the long term than most conservative interventions for tendinopathies of different locations. The included studies in our review did not allow for a similar strong conclusion on the long-term effect of corticosteroid injections. For non-electrotherapeutical physiotherapy, we agree with earlier reviews [14, 16, 18, 19, 21] that there is moderate evidence of a short-term effect of manipulation and exercise. Our review strengthens this conclusion with the inclusion of a recently published study [40]. In addition, we found moderate evidence of both short- and long-term beneficial effect of eccentric exercise and stretching.

# **Authors' conclusions**

#### Implications for practice

We found that both corticosteroid injection and manipulation with exercise gave a short-term benefit compared to control for treating lateral epicondylitis. At intermediate term, treatment with corticosteroid injection came out worse, while manipulation with exercise was not different from control. At long term, both treatments showed no benefit over control. For patients wanting treatment, it seems reasonable to recommend manipulation and exercise. For patients with mild symptoms, a wait-and-see approach would be appropriate. Though showing a large short-term benefit, the negative intermediate-term effect and uncertain longterm effect of corticosteroid injection make this treatment difficult to recommend. Eccentric

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## **BMJ Open**

exercise with stretching showed efficacy both on short- and long-term follow-up, but only in one study.

## Implications for research

We found few studies and some conflicting results on the long-term efficacy of corticosteroid injection. More trials or a meta-analysis with individual patient data from earlier studies might give better answers to the question on long-term effect.

For non-electrotherapeutical physiotherapy, more studies with a randomised, controlled design are needed. Blinding, for example by using a blinded assessor, should be applied wherever possible. The promising results of manipulation with exercise and eccentric exercise with stretching need further investigating.

Future studies should differentiate between acute and chronic complaints. Baseline levels of perceived pain, stress levels, handedness and presence of physical stress at work should be recorded. Standardization in the usage of outcome measures will enable data pooling and meta-analyses in future reviews. Studies investigating the combined effect of physiotherapy and corticosteroid injection treatments would also be useful. Most patients with acute lateral epicondylitis are treated in a general practice setting, and future research should be performed in such a setting.

# Acknowledgements

Morten Olaussen and Oeystein Holmedal designed the study, performed the searches, read articles, decided which articles to include, performed the data extractions, interpreted the findings and wrote the main manuscript. Morten Lindbaek designed the study, decided which articles to include, interpreted the findings and revised the manuscript. Soeren Brage decided which articles to include, interpreted the findings and revised the manuscript. Hiroko Solvang

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

did the statistical calculations and analysis, interpreted the findings and revised the manuscript.

# **Competing interests**

The authors declare that they have no competing interests.

# Funding

Our work was funded by The Fund for General Practice Research, The Norwegian Medical Association, Oslo, Norway.

# References

- Chard MD, Hazleman BL: Tennis elbow--a reappraisal. *Br J Rheumatol* 1989,28(3):186-190.
- Hamilton PG: The prevalence of humeral epicondylitis: a survey in general practice.
   *JR CollGenPract* 1986,36(291):464-465.
- 3. Kivi P: The etiology and conservative treatment of humeral epicondylitis. *ScandJRehabilMed* 1983,**15(1)**:37-41.
- 4. Hudak PL, Cole DC, Haines AT: Understanding prognosis to improve rehabilitation: the example of lateral elbow pain. *ArchPhysMedRehabil* 1996,**77(6)**:586-593.
- 5. Murtagh J: Tennis elbow. *AustFamPhysician* 1984, **13(1)**:51.
- Torp-Pedersen TE, Torp-Pedersen ST, Qvistgaard E, Bliddal H: Effect of glucocorticosteroid injections in tennis elbow verified on colour Doppler ultrasonography: evidence of inflammation. *Br J Sports Med* 2008,42(12):978-982.
- Alfredson H, Lorentzon R: Chronic tendon pain: no signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment? *CurrDrug Targets* 2002,3(1):43-54.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# **BMJ Open**

8.	Pattanittum P, Turner T, Green S, Buchbinder R: Non-steroidal anti-inflammatory
	drugs (NSAIDs) for treating lateral elbow pain in adults. Cochrane Database of
	Systematic Reviews 2013, May 31: CD003686.
9.	Buchbinder R, Green S, Youd JM, Assendelft WJ, Barnsley L, Smidt N: Shock way
	therapy for lateral elbow pain. Cochrane Database of Systematic Reviews 2009, Jan
	CD003524.
10.	Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft W:
	Acupuncture for lateral elbow pain. Cochrane Database of Systematic Reviews
	2008,Oct 8:CD003527.
11.	Brosseau L, Casimiro L, Milne S, Robinson V, Shea B, Tugwell P, Wells G: Deep
	transverse friction massage for treating tendinitis. Cochrane Database of Systematic
	Reviews 2009, Jan 21:CD003528.
12.	Struijs PA, Smidt N, Arola H, van Dijk CN, Buchbinder R, Assendelft WJ: Orthoti
	devices for the treatment of tennis elbow. Cochrane Database of Systematic Review
	2009,Jan 21:CD001821.
13.	Buchbinder R, Green S, Bell SN, Barnsley L, Smidt N, Assendelft WJ, Johnston R
	Surgery for lateral elbow pain. Cochrane Database of Systematic Reviews 2011, Ma
	16:CD003525.
14.	Barr S, Cerisola FL, Blanchard V: Effectiveness of corticosteroid injections compared
	with physiotherapeutic interventions for lateral epicondylitis: a systematic review.
	<i>Physiotherapy</i> 2009, <b>95(4)</b> :251-265.
15.	Coombes BK, Bisset L, Vicenzino B: Efficacy and safety of corticosteroid injection
	and other injections for management of tendinopathy: a systematic review of
	randomised controlled trials. Lancet 2010,376(9754):1751-1767.

- Nimgade A, Sullivan M, Goldman R: Physiotherapy, steroid injections, or rest for lateral epicondylosis? What the evidence suggests. *Pain Pract* 2005,5(3):203-215.
  - Smidt N, Assendelft WJ, Van der Windt DA, Hay EM, Buchbinder R, Bouter LM:
    Corticosteroid injections for lateral epicondylitis: a systematic review. *Pain*2002,96(1-2):23-40.
  - Bisset L, Paungmali A, Vicenzino B, Beller E: A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia. *BrJSports Med* 2005,39(7):411-422.
  - 19. Herd CR, Meserve BB: A systematic review of the effectiveness of manipulative therapy in treating lateral epicondylalgia. *J Man Manip Ther* 2008,**16(4)**:225-237.
  - Smidt N, Assendelft WJ, Arola H, Malmivaara A, Greens S, Buchbinder R, Van der Windt DA, Bouter LM: Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. *AnnMed* 2003,35(1):51-62.
  - Trudel D, Duley J, Zastrow I, Kerr EW, Davidson R, MacDermid JC: Rehabilitation for patients with lateral epicondylitis: a systematic review. *J Hand Ther* 2004,17(2):243-266.
  - 22. van Tulder MW, Suttorp M, Morton S, Bouter LM, Shekelle P: Empirical evidence of an association between internal validity and effect size in randomized controlled trials of low-back pain. *Spine (Phila Pa 1976)* 2009,**34(16)**:1685-1692.
  - 23. Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001,**323(7303)**:42-46.
  - Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2.: The Cochrane Collaboration; 2009.

# **BMJ Open**

25.	Moher D, Schulz KF, Altman DG: The CONSORT statement: revised
	recommendations for improving the quality of reports of parallel-group randomised
	trials. Lancet 2001,357(9263):1191-1194.
26.	Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild
	PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials
	for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol
	1998, <b>51(12)</b> :1235-1241.
27.	Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M: Reliability of the
	PEDro scale for rating quality of randomized controlled trials. Phys Ther
	2003, <b>83(8)</b> :713-721.
28.	Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP:
	Does quality of reports of randomised trials affect estimates of intervention efficacy
	reported in meta-analyses? Lancet 1998, <b>352(9128)</b> :609-613.
29.	Bisset L, Beller E, Jull G, Brooks P, Darnell R, Vicenzino B: Mobilisation with
	movement and exercise, corticosteroid injection, or wait and see for tennis elbow:
	randomised trial. <i>BMJ</i> 2006, <b>333</b> :939.
30.	Hay EM, Paterson SM, Lewis M, Hosie G, Croft P: Pragmatic randomised controlled
	trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis
	of elbow in primary care. BMJ: British Medical Journal 1999,319(7215):964-968.
31.	Lindenhovius A, Henket M, Gilligan BP, Lozano-Calderon S, Jupiter JB, Ring D:
	Injection of dexamethasone versus placebo for lateral elbow pain: a prospective,
	double-blind, randomized clinical trial. Journal of Hand Surgery - American Volume
	2008, <b>33(6)</b> :909-919.
32.	Martinez-Silvestrini JA, Newcomer KL, Gay RE, Schaefer MP, Kortebein P, Arendt
	KW: Chronic lateral epicondylitis: comparative effectiveness of a home exercise

program including stretching alone versus stretching supplemented with eccentric or concentric strengthening. Journal of hand therapy: official journal of the American Society of Hand Therapists 2005,18:411-419, quiz.

- 33. Newcomer KL, Laskowski ER, Idank DM, McLean TJ, Egan KS: Corticosteroid injection in early treatment of lateral epicondylitis. *Clinical journal of sport medicine:* officia ljournal of the Canadian Academy of Sport Medicine 2001,11:214-222.
- 34. Price R, Sinclair H, Heinrich I, Gibson T: Local injection treatment of tennis elbow hydrocortisone, triamcinolone and lignocaine compared. BrJRheumatol 1991,30(1):39-44.
- 35. Smidt N, Van der Windt DA, Assendelft WJ, Deville WL, Korthals-de Bos IB, Bouter LM: Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. *Lancet* 2002.**359(9307)**:657-662.
- 36. Toker S, Kilincoglu V, Aksakalli E, Gulcan E, Ozkan K: Short-term results of treatment of tennis elbow with anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture. Acta Orthopaedica et Traumatologica Turcica 2008,42:184-187.
- 37. Tonks JH, Pai SK, Murali SR: Steroid injection therapy is the best conservative treatment for lateral epicondylitis: a prospective randomised controlled trial. International Journal of Clinical Practice 2007,61(2):240-246.
- 38. Coombes BK, Bisset L, Brooks P, Khan A, Vicenzino B: Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral epicondylalgia: a randomized controlled trial. JAMA : the journal of the American Medical Association 2013,309(5):461-469.
- 39. Kochar M, Dogra A: Effectiveness of a specific physiotherapy regimen on patients with tennis elbow: Clinical study. *Physiotherapy* 2002,88(6):333-341.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# **BMJ Open**

40.	Peterson M, Butler S, Eriksson M, Svardsudd K: A randomized controlled trial of
	exercise versus wait-list in chronic tennis elbow (lateral epicondylosis). Upsala
	journal of medical sciences 2011,116(4):269-279.
1.	Selvanetti A, Barrucci A, Antonaci A, Martinez P, Marra S, Necozione S: Role of the
	eccentric exercise in the functional reeducation of lateral epicondylitis: a randomised
	controlled clinical trial. Medicina dello Sport 2003,56:103-113.
2.	Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-
	analyses. BMJ 2003,327(7414):557-560.
•	van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method guidelines for
	systematic reviews in the cochrane collaboration back review group. Spine
	2003, <b>28(12)</b> :1290-1299.
ļ.	Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability.
	Psychological bulletin 1979,86(2):420-428.
	Altay T, Gunal I, Ozturk H: Local injection treatment for lateral epicondylitis.
	ClinOrthopRelat Res 2002,(398):127-130.
	Croisier JL, Foidart-Dessalle M, Tinant F, Crielaard JM, Forthomme B: An isokinetic
	eccentric programme for the management of chronic lateral epicondylar tendinopathy.
	Br J Sports Med 2007,41(4):269-275.
7.	Dogramaci Y, Kalaci A, Savas N, Duman IG, Yanat AN: Treatment of lateral
	epicondilitis using three different local injection modalities: A randomized prospective
	clinical trial. Archives of Orthopaedic and Trauma Surgery 2009,129(10):1409-1414.
8.	Paungmali A, O'Leary S, Souvlis T, Vicenzino B: Hypoalgesic and
	sympathoexcitatory effects of mobilization with movement for lateral epicondylalgia.
	<i>PhysTher</i> 2003, <b>83(4)</b> :374-383.

49. Saartok T, Eriksson E: Randomized trial of oral naproxen or local injection of betamethasone in lateral epicondylitis of the humerus. Orthopedics 1986,9:191-194.

- 50. Vicenzino B, Paungmali A, Buratowski S, Wright A: Specific manipulative therapy treatment for chronic lateral epicondylalgia produces uniquely characteristic hypoalgesia. Manual Therapy 2001,6(4):205-212.
- 51. Viswas R, Ramachandran R, Korde Anantkumar P: Comparison of effectiveness of supervised exercise program and Cyriax physiotherapy in patients with tennis elbow (lateral epicondylitis): a randomized clinical trial. *TheScientificWorldJournal* 2012,012:939645.
- Neveloff JL, Fuchs SC, Moreira LB: Meta-analyses and Forest plots using a microsoft 52. excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC *research notes* 2012,**5**:52.
- 53. Cook JL, Purdam CR: Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 2009,43(6):409-416.
- 54. Haahr JP, Andersen JH: Prognostic factors in lateral epicondylitis: a randomized trial with one-year follow-up in 266 new cases treated with minimal occupational intervention or the usual approach in general practice. *Rheumatology (Oxford)* 2003,42(10):1216-1225.
- 55. Gaujoux-Viala C, Dougados M, Gossec L: Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2009,68(12):1843-1849.

# **BMJ Open**

# FIGURES AND TABLES

uploaded as web only data:

 Table 1: Demographics, treatments and outcome measures in the ten included studies

 Table 2: Quality rating of included studies by assessing internal and external validity with the PEDro scale

 Table 3: Effect size of improvement rate, reduction in pain and increase in grip

 strength for corticosteroid injection

 Table 4: Effect size of treatment effects for non-electrotherapeutic physiotherapy


Figure 1: Outline of the selection process


Figure 2: Forest-plot of effect sizes for corticosteroid injection

Figure 3: Forest-plot of effect sizes for non-electrotherapeutic physiotherapy

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.


# Figure 1: Outline of the selection process






Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**BMJ Open** 





1	_								
2	Concentric e					un hur f			
3	DASH score	(0-100, 100		plaints, i term (4-:			vours treat	ment) SMD (95% Cl)	
4			Short	term (4	iz week	5)			
5	M-Silvestrini								
6	W Sivestini				_				
7		-1,00	-0,50	0,00	0	0,50	1,00		
8									
9	Pain SMD (9	5% Cl) - ne	gative value	e favours	s treatm	ent			
			Short t	term (4-:	12 week	s)			
10				1		_			
11	M-Silvestrini			-+		_			
12		[				1			
13		-1,00	-0,50	0,00	0	0,50	1,00		
14	Pain free gri	n strength	affected ar	m SMD (	(95% CI)				
15	i un nee Bri	poucingui		term (4-:		s)			
16						-,			
17	M-Silvestrini	i —							
18		Γ	1						
19		-1,00	-0,50	0,00		0,50	1,00		
20									
	Improvemen							d, elbow support)	
21	improvemer	IL/SUCCESS		term (4-:			ι	Intermediate term (26 weeks)	Long term (52 weeks)
22			5110111	tenn (4	IZ WEEK	5/		intermediate term (20 weeks)	Long term (32 weeks)
23	Selvanetti								
24									
25									0,00 50,00 100,00 150,00 200,00
26									
27	Pain on Ko-s	cale (large					CI)		
28			Short t	term (4-:	12 week	s)		Intermediate term (26 weeks)	Long term (52 weeks)
29	Selvanetti	1							
30	Selvanetti					-			
31		0,00 1,	00 2,00	3,00	4,00	5,00	6,00		0,00 1,00 2,00 3,00 4,00 5,00 6,00
32		-,,	,	-,	.,	-,	-,		6,00 1,00 2,00 5,00 1,00 5,00 6,00
	Grip strengt	h on Ko-sca	le (larger v	alue me	ans grea	iter stren	gth) SMD (		
33	Grip strengtl	h on Ko-sca		alue me term (4-:			gth) SMD (9	95% CI) Intermediate term (26 weeks)	Long term (52 weeks)
33 34		h on Ko-sca					gth) SMD (9		Long term (52 weeks)
33 34 35	Grip strengtl Selvanetti	h on Ko-sca					gth) SMD (9		Long term (52 weeks)
33 34 35 36			Short t	term (4-:	12 week	s)	1		
33 34 35			Short t	term (4-:			gth) SMD (9		Long term (52 weeks)
33 34 35 36			Short t	term (4-:	12 week	s)	1		
33 34 35 36 37			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
33 34 35 36 37 38 39			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> <li>51</li> </ul>			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
33 34 35 36 37 38 39 40 41 42 43 44 50 51 52			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
33 34 35 36 37 38 39 40 41 42 43 44 50 51 52			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
33 34 35 36 37 38 39 40 41 42 43 44 50 51 52			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{c} 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 34\\ 45\\ 46\\ 47\\ 48\\ 95\\ 51\\ 25\\ 35\\ 55\\ 57\\ \end{array}$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{c} 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 34\\ 45\\ 46\\ 47\\ 48\\ 95\\ 51\\ 25\\ 35\\ 55\\ 57\\ \end{array}$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			Short t	term (4-:	12 week	s)	1	Intermediate term (26 weeks)	0,00 1,00 2,00 3,00 4,00 5,00

Table 1: Demogr	aphics, treat	tments and ou	utcome measures in th	BMJ Open ne eleven included studies		6/bmjopen- copyright 2000come measures	
Study and year setting and sample size	Women (percentages)	Age (mean if not otherwise stated)	Duration of complaints (weeks)	Treatment groups	Control group	Outcome measures	Follow up (weeks)
Bisset et al. 2006 Outpatient clinic n=198	35	47,6 (SD 7.8)	22 (median) (IQR: 12-42)	1: 10 mg triamcinolone and 1 ml lidocaine against the most painful point repeated after 2weeks     Elbow manipulation (manipulation with mowement) and excercise 8 sessions of 30 minutes duration during a 6 week period and home exercise	Information, wait-and-see	(excerpts)	52
Coombes et al. 2013 Community setting n=165	38	49.7 (SD 8.1)	16 (median) (IQR 10-26)	One injection of 1 ml triamcinolone 10 ml/ml and     1 ml lignocaine 1% against site of greatest palpable tenderness     at the common extensor origin     Elbow manipulation (manipulation with mowement) and excercise     8 sessions of 30 minutes duration     during a 8 week period and home exercise     One injection of triamcinolone followed by 8 sessions of     elbow manipulation and excersie, home excercise for 8 weeks         (not considered in this review)	Placebo injection 0.5 ml 0.9 % isotonic saline	Eprove Ant on 6-point Likert-scale Sine year fecurrence Rain on @s NTEE Restionnaire 11 Broco 60-50 quality of life score Eras mush to ush to ush	52
Hay et al. 1999 General practice n=164	Group 1: 41 (Group 2: 53) Control: 48	Age ≥ 45: (percentages) Group 1: 70 (Group 2: 68) Control: 38	9 (mean) Percentage with pain >3 months: Group 1: 36 (Group 2: 25) Control: 31	One injection of methylprednisolone 20 mg and 0.5 ml 1% lignocaine towards tender spot     Naproxen po 500 mg bid for 2 weeks (not considered in this review)	Placebo tablets	Apported int on 5-point Likert-scale Part of the scale Part of the s	52
Price et al. 1991 Outpatient clinic n=88	Group 1: 48 Group 2: 43 Control: 38	Group 1: 47 Group 2: 47 Control: 46 <i>(median)</i>	Group 1: 20 (6-150) Group 2: 36 (6-154) Control: 16 (6-150) (median and range)	Hydrocortisone 25 mg and 1% lidocaine against tender point (2 ml fluid) (55% received 2 injections)     Triamcinolone 10 mg and 1% lidocaine (30% received 2 injections)	2 ml 1% lidocaine against tender point	A in on CAS moderness score main-weathed grip strength D D D D D D D D D D D D D D D	24
Smidt et al. 2002 General practice n=185	Group 1: 55 (Group 2: 44) Control: 53	Group 1: 47 (Group 2: 48) Control: 46 <i>(median)</i>	Group 1: 11 (8-16) (Group 2: 11 (8-21)) Control: 11 (8-21) (median and IQR)	<ol> <li>1: 10 mg triamcinolone and 1 ml lidocain againt all tender points up to 3 injections</li> <li>2: One group reveived physiotherapy with ultrasound (not considered in this review)</li> </ol>	Wait-and-see (some were prescribed naproxen po 1000 mg daily)	Aprovement on 6-point Likert scale Severity of complaint on scale Distributionaires GS Paximum prip strength (MGS) DessueGain measurements Chitisfaction with treatment	52
Toker et al. 2008 Outpatient clinic n=21	43	45 (range 19-72)	not stated	One injection of 1 ml metylprednisolon and 1 ml prilocain with oral diklofenac 3 tablets (dose not stated) and etofenamat topically	Oral diklofenac 3 tablets (dose not stated) and etofenamat topically	Proceived abscense of pain Second of pain on palpation Wer lateral epicondyle and on cometric dorsification of wrist Din score	4
Lindenhovius et al. 2008 Outpatient clinic n=64	Treatment: 63 Control: 60	Treatment: 50 +/- 8 Control: 51+/- 10	Treatment: 12 +/- 4 (2-20) Control: 8 +/- 4 (1-20)	4 mg dexamethasone and 10 mg lidocaine (2 ml fluid) against the most tender spot, fanning of the needle. One injection - but 6 of 64 got 2 injections.	10 mg lidocain, 2 ml fluid total	ASH questionnaire * Pain on VAS Orip strength	26
Newcomer et al. 2001 Outpatient clinic n=39	51	Treatment: 46.0 +/- 7.0 Control: 44.6+/- 7.6	Treatment: 3.2 (mean) SD 0.8 Control: 3.4 (mean) SD 0.9	One injection of 5 ml 4:1 0.25% bupivacaine and 6 mg/ml betamethasone against tender point. Home excercises consisting of ice massage, wrist stretching and progressive eccentric and concentric exercises	Placeboinjection of 5 ml bupivacaine Home excercises consisting of ice massage, wrist stretching and progressive eccentric and concentric exercises	Arrow of the second secon	26
M-Silvestrini et al. 2005 Outpatient clinic n=94	47	45,5 +/- 7.7	more than 12	<ol> <li>Concentric strengthening 3x10 repetitions once daily and wrist stretching twice daily for 6 weeks</li> <li>Eccentric strengthening 3x10 repetitions once daily and wrist stretching twice daily for 6 weeks</li> </ol>	Wrist stretching twice daily for 6 weeks	PFGS Pain on VAS PRFEQ Auestionnaire† Patient's log of training DASH aussionnaire *	6
Peterson et al. 2011 General practice n=81	42	48	Treatment: 107 Control: 96	Three-month daily exercise regime performed at home with progressively increasing load on the extensor muscles	Information, wait-and-see	Pain on MAS during contraction and during elongation of forearm muscles Muscle spength with hand-held dynanometer DASH of the stronnaire	12
Selvanetti et al. 2003 Setting not stated n=62	Treatment: 45 Control: 48	Treatment: 41,3 Control: 40,5	Treatment: 28 (8-40) Control: 29 (12-44)	4 weeks home-exercise after instruction from physiotherapist consisting of stretching and eccentric excercise Counseling and use of elbow support	Sham ultrasound 20 sessions Counseling and use of elbow support	Ko scoring system (includes clench test, Thomse const and pain). Verhaar proving system on global improvement Subject Mimprovement VAS scale (0-100)	44 (24-56)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 33 of 65

### **BMJ Open**

### Table 2: Quality rating of studies by assessing internal and external validity with the PEDro scale

e 2: Quality rating of studies by a		iternai anu	external v	andity with	n the PEDr	o scale Study			دة/bmjopen-2013-003564 o by copyright, includin∯t ⊛				
PEDro criterion	Bisset	Coombes	Нау	Price	Smidt	Toker	Lindenhovius	Newcomer	M-Sil Gestrini <sup>4</sup>	Peterson	Selvanetti	Kochar	
eligibility criteria were specified subjects were randomly allocated to groups	1	<u>1</u>	1	1	1	<u>1</u> 1	1	1	<u> </u>	1	<u>1</u>	1	
allocation was concealed	1	1	1	0	1	0	1	0	US NG	1	1	0	
he groups were similar at baseline regarding the nost important prognostic indicators	1	1	1	1	1	1	1	1	ies Oc	) 1	1	1	
here was blinding of all subjects	Ö	0	0	1	0	0	1	1		· 0	0	0	
here was blinding of all therapists who administered									<u>е пğ</u>			0	
he therapy here was blinding of all assessors who measured at	0	0	0	0	0	0	1	1	ber 2013. Downloaded Erasmushogeschool . afed to text and data .	0	0		
here was blinding of all assessors who measured at east one key outcome	1	1	1	1	1	0	1	0	jd Su	0	0	0	
neasures of at least one key outcome were obtained				•	•	•	•	2					
rom more than 85% of the subjects initially allocated							-		te			0	
o groups all subjects for whom outcome measures were	1		1	1	1	1	0	1		1	1		
available, received the treatment or control condition									ଛା ଭୁଁ ≷				
as allocated or, where this was not the case, data for									nk scl			0	
at least one key outcome was analysed by "intention o treat"	1	1	1	4	4	4	4	4	d o a	1	1		
he results of between-group statistical comparisons	1				I	I	I	1	<u></u>		1		
are reported for at least one key outcome	1	1	1	1	1	1	1	1			1	1	
he study provides both point measures and		1	4						a trom n 1. mining,			1	_
neasures of variability for at least one key outcome Total PEDro score	8	1 8	1 8	8	8	1 6	<u>1</u> 9	1 8		1 7	<u> </u>	4	
Sum criteria 2 to 11, maximum score is 10)	•	0	0	0	0	0	9	0	ç Ş		1	4 EXLUDED	
									nining, AI training, and similar technologies.				

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2
3
4
5
6
1
8
9
10
11
12
10
14
16
17
18
19
20
21
22
23
24
13456789101234156789011234156789012222425678901323345678901123456789011234456789012234256789013233456789040
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 44
41 42
42 43
43 44
44 45
46
47
48
48 49
50
50 51
52
53
54
52 53 54 55
56
56 57
58
59
60

# Table 3. Effect size of improvement rate, reduction in pain and increase ingrip strength for corticosteroid injection

	Short term 4-12 weeks	Intermediate term 26 weeks	Long term 52 weeks
verall improvement RR (95%	S CI) RR>1 favours tr	eatment	
Corticosteroid injection (C	SI) vs no intervention o	r NSAIDs	
Bisset	2.94 (1.90 to 4.45)*	0.55 (0.41 to 0.73)*	0.75 (0.62 to 0.90)
Coombes	7.32 (2.83 to 18.94)*	0.68 (0.50 to 0.92)*	0.91 (0.77 to 1.06)
Нау	1.60 (1.18 to 2.17)*	0.77 (0.60 to 0.98)*	1.07 (0.88 to 1.30)
Smidt	2.86 (1.96 to 4.16)*		0.84 (0.68 to 1.02
Toker	2.27 (1.04 to 4.97)*	_	-
Pooled	2.27 (1.04 (0 4.57)	0.66 (0.53 to 0.81)*	0.87 (0.73 to 1.04)
	-	$p=0.21 l^2=35\%$	$p=0.07 l^2=58\%$
Heterogeneity	>65%	p=0.211 =33%	μ-0.07 T -38%
in (negative value favours t	reatment) SMD (95%	% CI)	
CSI vs no intervention or N	<b>NSAIDs</b>		
Bisset	-1.43 (-1.83 to -1.04)*	0.40 (0.04 to 0.76)*	0.27 (-0.08 to 0.62
Coombes	-2.14 (-2.68 to -1.60)*	0.16 (-0.28 to 0.59)	0.08 (-0.35 to 0.52
Hay	-1.05 (-1.45 to -0.66)*	0.42 (0.04 to 0.80)*	1.35 (0.94 to 1.76)
Smidt	-1.49 -(1.89 to -1.08)*		0.15 (-0.20 to 0.51
		0.27 (-0.09 to 0.63)	0.15 (-0.20 (0 0.5)
Toker	-1.14 (-2.07 to -0.22)*	-	-
Pooled	-1.43 (-1.64 to -1.23)*	0.32 (0.13 to 0.51)*	-
Heterogeneity	p=0.032 I <sup>2</sup> =62%	p=0.79 l <sup>2</sup> =0%	>65%
CSI vs lidocaine injection			
Lindenhovius	-0.25 (-0.74 to 0.24)	0.27 (-0.30 to 0.84)	-
Price 1	-1.06 (-1.63 to -0.49)*	3.13 (2.31 to 3.95)*	-
Price 2	-3.37 (-4.20 to -2.54)*	1.55 (0.93 to 2.17)*	-
Pooled	-		-
Heterogeneity	>65%	>65%	-
All above pooled		_	
Heterogeneity	>65%	>65%	
CSI, excercise and stretchi		tabias	
	ng vs excersise and stre	liching	
	-	0.27 ( 1.04 += 0.20)	
Newcomer <sup>+</sup>	0.16 (-0.49 to 0.81)	-0.37 (-1.04 to 0.30)	-
	0.16 (-0.49 to 0.81)		- CI)
<b>Newcomer</b> <sup>+</sup>	0.16 (-0.49 to 0.81)		-
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N	0.16 (-0.49 to 0.81) <b>ive value favours tre</b>	eatment) SMD (95%	
Newcomer <sup>+</sup> aximum grip strength (posit	0.16 (-0.49 to 0.81) <b>ive value favours tre</b>		
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling	0.16 (-0.49 to 0.81) <b>ive value favours tre</b>	eatment) SMD (95%	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)*	eatment) SMD (95% -0.38 (-0.74 to -0.02)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30)	eatment) SMD (95% -0.38 (-0.74 to -0.02)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N Smidt no pooling CSI vs lidocaine injection Lindenhovius Price 1	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48)	eatment) SMD (95% -0.38 (-0.74 to -0.02)* - 0.07 (-0.50 to 0.64) -0.98 (-1,58 to -0.38)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30)	eatment) SMD (95% -0.38 (-0.74 to -0.02)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2 Pooled	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48) 2.31 (1.62 to 3.00)*	eatment) SMD (95% -0.38 (-0.74 to -0.02)* - 0.07 (-0.50 to 0.64) -0.98 (-1.58 to -0.38)* -0.86 (-1.44 to -0.29)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48)	eatment) SMD (95% -0.38 (-0.74 to -0.02)* - 0.07 (-0.50 to 0.64) -0.98 (-1,58 to -0.38)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2 Pooled	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48) 2.31 (1.62 to 3.00)*	eatment) SMD (95% -0.38 (-0.74 to -0.02)* - 0.07 (-0.50 to 0.64) -0.98 (-1.58 to -0.38)* -0.86 (-1.44 to -0.29)*	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2 Pooled Heterogeneity	0.16 (-0.49 to 0.81) <b>Sive value favours tre</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48) 2.31 (1.62 to 3.00)*	eatment) SMD (95% -0.38 (-0.74 to -0.02)* - 0.07 (-0.50 to 0.64) -0.98 (-1,58 to -0.38)* -0.86 (-1.44 to -0.29)* - - - - - - - - - - - - -	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2 Pooled Heterogeneity All above pooled Heterogeneity	0.16 (-0.49 to 0.81) <b>Sive value favours tree</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48) 2.31 (1.62 to 3.00)* - >65%	eatment) SMD (95% -0.38 (-0.74 to -0.02)* 0.07 (-0.50 to 0.64) -0.98 (-1.58 to -0.38)* -0.86 (-1.44 to -0.29)* -565% -0.48 (-0.73 to -0.24)* $p=0.04 l^2=64\%$	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N Smidt no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2 Pooled Heterogeneity CSI, excercise and stretchi	0.16 (-0.49 to 0.81) ive value favours trees NSAIDS -1.42 (-1.82 to -1.03)* - -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48) 2.31 (1.62 to 3.00)* - >65% ing vs excersise and strees	eatment) SMD (95% -0.38 (-0.74 to -0.02)* 0.07 (-0.50 to 0.64) -0.98 (-1.58 to -0.38)* -0.86 (-1.44 to -0.29)* -565% -0.48 (-0.73 to -0.24)* $p=0.04 l^2=64\%$	
Newcomer <sup>+</sup> aximum grip strength (posit CSI vs no intervention or N <u>Smidt</u> no pooling CSI vs lidocaine injection Lindenhovius Price 1 Price 2 Pooled Heterogeneity All above pooled Heterogeneity	0.16 (-0.49 to 0.81) <b>Sive value favours tree</b> NSAIDs -1.42 (-1.82 to -1.03)* -0.19 (-0.68 to 0.30) -0.06 (-0.59 to 0.48) 2.31 (1.62 to 3.00)* - >65%	eatment) SMD (95% -0.38 (-0.74 to -0.02)* 0.07 (-0.50 to 0.64) -0.98 (-1.58 to -0.38)* -0.86 (-1.44 to -0.29)* -565% -0.48 (-0.73 to -0.24)* $p=0.04 l^2=64\%$	

\*: statistically significant (p<0.05) Price 1: hydrocortisone vs. lidocaine Price 2: triamcinolone vs lidocaine \*: The values for Newcomer are given as <u>change</u> in pain and and <u>change</u> in <u>pain free</u> grip strength

Coombes4.00 (1.46 to 10.94)*1.06 (0.89 to 1.28)1.08 (0.97Pooled2.75 (2.09 to 3.62)*0.99 (0.75 to 1.30)1.05 (0.77)Heterogeneity $p=0.37$ $l^2=0\%$ $p=0.33$ $l^2=0\%$ $p=0.33$ ( $l^2=0\%$ Pain SMD (standardised mean difference) (95% CI) - negative value favours treatBisset $-0.63$ ( $l-0.99$ to $-0.27$ )* $-0.25$ ( $l-62$ to 0.11) $-0.38$ ( $l-77$ Coombes $-1.27$ ( $-1.74$ to $-0.79$ )* $0.00$ ( $-0.44$ to $0.44$ ) $0.00$ ( $-0.47$ $l-0.23$ ( $l-0.57$ Heterogeneity $p>655\%$ $p=0.39$ $l^2=0\%$ $p=0.18$ Pain free grip strength ratio affected/ unaffected arm SMD (95%)Bisset $0.76$ ( $0.39$ to $1.13$ )* $0.20$ ( $-0.47$ to $0.56$ ) $0.17$ ( $-0.1$ Exercise vs no interventionDASH score (0-100, 100 most complaints, negative value favours treatment) SMDPeterson $-0.03$ ( $-0.47$ to $0.40$ ) $ -$ Pain on maximum voluntary contraction SMD (95% CI) - negative value favours trePeterson $-0.02$ ( $-0.68$ to $0.19$ ) $-$ Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment) SMDM-Silvestrini $-0.02$ ( $-0.68$ to $0.60$ ) $-$ Pain free grip strength affected arm SMD (95%)M-Silvestrini $-0.24$ ( $-0.39$ to $0.27$ ) $-$ Pain free grip strength affected arm SMD (95%)M-Silvestrini $-0.24$ ( $-0.39$ to $0.27$ ) $-$ Pain free grip strength affected arm SMD (95%)M-Silvestrini $-0.41$ ( $-0.39$ to $0.68$ ) $-$ Pain free grip strength affected arm SMD (95% CI)			Short term 4-12 weeks	Intermediate term 26 weeks	Long ter 52 wee
Bisset $2.44 (1.54 to 3.85)^*$ $0.94 (0.78 to 1.12)$ $1.04 (0.9; CombesPooled2.75 (200 to 3.62)^*0.99 (0.75 to 1.30)1.05 (0.77 tetrogeneity)Pooled2.75 (2.90 to 3.62)^*0.99 (0.75 to 1.30)1.05 (0.77 tetrogeneity)Pain SMD (standardised mean difference) (95% CI) - negative value favours treattBisset-0.63 (0.99 to -0.27)^*0.25 (0.62 to 0.11)-0.38 (-0.72 tetrogeneity)Pooled-1.27 (1.74 to -0.79)^*0.00 (0.44 to 0.44)0.00 (0.44 to 0.44)Pooled-1.27 (1.74 to -0.79)^*0.00 (0.44 to 0.44)0.00 (0.44 to 0.44)Pooled-0.15 (0.43 to 0.13)-0.23 (-0.57 tetrogeneity)p.65\%Pooled-0.15 (0.43 to 0.13)-0.23 (-0.56 tetrogeneity)Pain free grip strength ratio affected/ unaffected arm SMD (95%)Bisset0.76 (0.39 to 1.13)^*0.20 (-0.47 to 0.56)0.17 (-0.17 tetrogeneity)DASH score (0-100, 100 most complaints, negative value favours treatment) SMDPeterson-0.03 (-0.74 to 0.40)-Pain on maximum voluntary contraction SMD (95% CI) - negative value favours treatment)Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment)M-Silvestrini-0.02 (-0.67 to 0.49)-Pain SMD (95% CI) - negative value favours treatment)M-Silvestrini-0.04 (-0.57 to 0.49)-Pain free grip strength affected arm SMD (95%)-M-Silvestrini-0.26 (-0.79 to 0.27)-Pain free grip strength affected arm SMD (95% CI)-$	Manipulatio	on and exercise v	s no intervention		
Bisset $2.44 (1.54 to 3.85)^*$ $0.94 (0.78 to 1.12)$ $1.04 (0.9; CombesPooled2.75 (200 to 3.62)^*0.99 (0.75 to 1.30)1.05 (0.77 tetrogeneity)Pooled2.75 (2.90 to 3.62)^*0.99 (0.75 to 1.30)1.05 (0.77 tetrogeneity)Pain SMD (standardised mean difference) (95% CI) - negative value favours treattBisset-0.63 (0.99 to -0.27)^*0.25 (0.62 to 0.11)-0.38 (-0.72 tetrogeneity)Pooled-1.27 (1.74 to -0.79)^*0.00 (0.44 to 0.44)0.00 (0.44 to 0.44)Pooled-1.27 (1.74 to -0.79)^*0.00 (0.44 to 0.44)0.00 (0.44 to 0.44)Pooled-0.15 (0.43 to 0.13)-0.23 (-0.57 tetrogeneity)p.65\%Pooled-0.15 (0.43 to 0.13)-0.23 (-0.56 tetrogeneity)Pain free grip strength ratio affected/ unaffected arm SMD (95%)Bisset0.76 (0.39 to 1.13)^*0.20 (-0.47 to 0.56)0.17 (-0.17 tetrogeneity)DASH score (0-100, 100 most complaints, negative value favours treatment) SMDPeterson-0.03 (-0.74 to 0.40)-Pain on maximum voluntary contraction SMD (95% CI) - negative value favours treatment)Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment)M-Silvestrini-0.02 (-0.67 to 0.49)-Pain SMD (95% CI) - negative value favours treatment)M-Silvestrini-0.04 (-0.57 to 0.49)-Pain free grip strength affected arm SMD (95%)-M-Silvestrini-0.26 (-0.79 to 0.27)-Pain free grip strength affected arm SMD (95% CI)-$	Overa	all improvement	RR (relative risk) (95% (	(1) - RR>1 fayours treatr	ment
Pooled2.75 (2.09 to 3.62)*0.99 (0.75 to 1.30)1.05 (0.75 to 1.30)Heterogeneity $p=0.37$ $r=0\%$ $p=0.33$ $r=0\%$ Pain SMD (standardised mean difference) (95% CI) - negative value favours treatBisset $-0.63$ (-0.99 to $-0.27$ )* $-0.25$ (-0.62 to 0.11) $-0.38$ (-0.77Coombes $-1.27$ (-1.74 to $-0.79$ )* $-0.00$ (-0.44 to 0.44) $-0.00$ (-0.44 to 0.44) $-0.00$ (-0.44 to 0.44)Pooled $ -0.15$ (-0.43 to 0.13) $-0.23$ (-0.57Heterogeneity $p>55\%$ $p=0.39$ $r=0.39$ Pain free grip strength ratio affected/ unaffected arm SMD (95%)Bisset $0.76$ (0.39 to 1.13)* $0.20$ (-0.47 to 0.56) $0.17$ (-0.1Exercise vs no interventionDASH score (0-100, 100 most complaints, negative value favours treatment) SMDPain on maximum voluntary contraction SMD (95% CI) - negative value favours treatment)Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment)Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment)M-Silvestrini $-0.07$ (-0.64 to 0.60) $-$ M-Silvestrini $-0.04$ (-0.57 to 0.49) $-$ Pain SMD (95% CI) - negative value favours treatment)M-SilvestriniM-Silvestrini $-0.26$ (-0.79 to $0.27$ ) $-$ Pain free grip strength affected arm SMD (95%) $-$ M-Silvestrini $-0.26$ (-0.79 to $0.27$ ) $-$ Pain free grip strength affected arm SMD (95% CI) $-$ M-Silvestrini $-0.44$ (-0.38 to $0.20$ ) $-$ Pain free grip strength aff	<b>O</b> vere				1.04 (0.93 to
Heterogeneity $p=0.37$ $r^2=0\%$ $p=0.57$ Pain SMD (standardised mean difference) (95% CI) - negative value favours treat Bisset $-0.63$ (-0.99 to $-0.27$ )* $-0.25$ (-0.62 to 0.11) $-0.38$ (-0.74 Combes $-1.27$ ( $-1.74$ to $-0.79$ )* $-0.025$ ( $-0.62$ to 0.11) $-0.38$ ( $-0.74$ CombesPooled $-1.27$ ( $-1.74$ to $-0.79$ )* $-0.015$ ( $-0.43$ to 0.13) $-0.23$ ( $-0.57$ 		Coombes	4.00 (1.46 to 10.94)*		1.08 (0.99 to
Pain SMD (standardised mean difference) (95% CI) - negative value favours treat Bisset $0.63 (-0.99 \text{ to} -0.27)^*$ $0.25 (-0.62 \text{ to} 0.11)$ $0.38 (-0.74)^*$ Coombes $-1.27 (-1.74 \text{ to} -0.79)^*$ $0.00 (-0.44 \text{ to} 0.44)$ $0.00 (-0.47)^*$ $0.02 (-0.74 \text{ to} 0.13)$ $-0.23 (-0.57)^*$ Heterogeneity $p > 65\%$ $p = 0.39 T^2 - 0\%$ $p = 0.13$ Pain free grip strength ratio affected/unaffected arm SMD (95%)Bisset $0.76 (0.39 \text{ to} 1.13)^*$ $0.20 (-0.47 \text{ to} 0.56)$ $0.17 (-0.17)^*$ Exercise vs no interventionDASH score (0-100, 100 most complaints, negative value favours treatment) SMDPeterson $-0.03 (-0.47 \text{ to} 0.40)$ $-$ Pain on maximum voluntary contraction SMD (95% CI) - negative value favours treatment)Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment)Pain on maximum muscular elongation SMD (95% CI) - negative value favours treatment)MCDM-Silvestrini $-0.07 (-0.46 \text{ to} 0.60)$ Pain SMD (95% CI) - negative value favours treatment)M-Silvestrini $-0.04 (-0.57 \text{ to} 0.49)$ Pain free grip strength affected arm SMD (95%)M-SilvestriniM-SilvestriniOAGH (-0.39 \text{ to} 0.41) (-0.39 \text{ to} 0.68)Pain free grip strength affected arm SMD (95%)M-Silvestrini0.14 (-0.39 to} 0.68)Pain free grip strength affected arm SMD (95%)M-Silvestrini0.41 (-0.13 to} 0.95)Pain free grip strength affected arm SMD (95% CI)Pain free grip strength affected arm SMD (95% CI)M-Silvestrin					1.05 (0.75 to
Bisset $-0.63 (-0.99 \text{ to } -0.27)^*$ $-0.25 (-0.62 \text{ to } 0.11)$ $-0.38 (-0.74)^*$ Coombes $-1.27 (-1.74 \text{ to } -0.79)^*$ $0.00 (-0.44 \text{ to } 0.44)$ $0.00 (-0.47 \text{ to } 0.23 (-0.5)^*$ Pooled $ -0.15 (-0.43 \text{ to } 0.13)$ $-0.23 (-0.5)^*$ Heterogeneity $p>65\%$ $p=0.39 f^2 - 0\%$ $p=0.18$ Pain free grip strength ratio affected/ unaffected arm SMD (95%)Bisset $0.76 (0.39 \text{ to } 1.13)^*$ $0.20 (-0.47 \text{ to } 0.56)$ $0.17 (-0.17)^*$ Exercise vs no interventionDASH score (0-100, 100 most complaints, negative value favours treatment) SMDPeterson $-0.03 (-0.47 \text{ to } 0.40)$ $-$ Pain on maximum voluntary contraction SMD (95% CI) - negative value favours tre Peterson $-0.24 (-0.68 \text{ to } 0.19)$ $ -$ Pain on maximum muscular elongation SMD (95% CI) - negative value favours tree Peterson $-0.24 (-0.68 \text{ to } 0.60)$ $ -$ Pain SMD (95% CI) - negative value favours treatment M-Silvestrini $-0.02 (-0.79 \text{ to } 0.27)$ $ -$ Pain free grip strength affected arm SMD (95%) M-Silvestrini $-0.26 (-0.79 \text{ to } 0.27)$ $ -$ DASH score (0-100, 100 most complaints, negative value favours treatment)SMD MDASH score (0-100, 100 most complaints, negative value favours treatment)SMDM-Silvestrini $-0.26 (-0.79 \text{ to } 0.27)$ $ -$ Pain free grip strength affected arm SMD (95%) M-Silvestrini $-0.26 (-0.79 \text{ to } 0.27)$ $-$ DASH score (0-100, 100 most complaints, negative value favours treatment)SMDM-Silv		Heterogeneity	p=0.37 l <sup>2</sup> =0%	p=0.33 l <sup>2</sup> =0%	p=0.57 l <sup>2</sup> =
Coombes $-1.27 (+1.74 \text{ to } -0.79)^*$ $0.00 (-0.44 \text{ to } 0.44 \text{ to } 0.00 (-0.47 \text{ to } 0.23 (-0.57 \text{ Heterogeneity})p > 65\%p = 0.39 I^2 = 0\%p = 0.23 (-0.57 \text{ Heterogeneity})p = 0.5\%p = 0.39 I^2 = 0\%p = 0.18Pain free grip strength ratio affected/ unaffected arm SMD (95%)Bisset0.76 (0.39 \text{ to } 1.13)^*0.20 (-0.47 \text{ to } 0.56)0.17 (-0.17 \text{ co } 0.17 \text{ co } 0.17 \text{ co } 0.17 (-0.17 \text{ co } 0.100, 100 \text{ most complaints, negative value favours treatment) SMDPaterson-0.03 (-0.47 \text{ to } 0.40) -Pain on maximum voluntary contraction SMD (95% Cl) - negative value favours trePeterson-0.24 (-0.68 \text{ to } 0.19)-Pain on maximum muscular elongation SMD (95% Cl) - negative value favours trePeterson-0.24 (-0.68 \text{ to } 0.19)-Pain on maximum muscular elongation SMD (95% Cl) - negative value favours treatment)SMDMSH score (0-100, 100 most complaints, negative value favours treatment)SMDM-Silvestrini-0.26 (-0.79 \text{ to } 0.27)-Pain free grip strength affected arm SMD (95%)M-Silvestrini-0.26 (-0.79 \text{ to } 0.27)-Pain free grip strength affected arm SMD (95%)M-Silvestrini-0.24 (-0.39 \text{ to } 0.68)-Pain free grip strength affected arm SMD (95%)M-Silvestrini-0.24 (-0.39 \text{ to } 0.27)-DASH score (0-100, 100 most complaints, negative value favours treatment)SMDM-Silvestrini-0.24 (-0.39 \text{ to } 0.27)-Pain free grip strength affected arm SMD (95%)M-Silvestrini -M-Silvestrini$	Pain S				
Pooled Heterogeneity0.15 (-0.43 to 0.13) $p=0.39$ l <sup>2</sup> =0%-0.23 (-0.5 $p=0.18$ Pain free grip strength ratio affected/ unaffected arm SMD (95%) Bisset0.76 (0.39 to 1.13)*0.20 (-0.47 to 0.56)0.17 (-0.1Exercise vs no interventionDASH score (0-100, 100 most complaints, negative value favours treatment) SMD Peterson-0.03 (-0.47 to 0.40)-Pain on maximum voluntary contraction SMD (95% Cl) - negative value favours tre Peterson-0.30 (-0.74 to 0.14)-Pain on maximum muscular elongation SMD (95% Cl) - negative value favours tre Peterson-0.24 (-0.68 to 0.19)-Pain on maximum muscular elongation SMD (95% Cl) - negative value favours treatment M-SilvestriniPoin SMD (95% Cl) - negative value favours treatment M-SilvestriniM-Silvestrini-0.04 (-0.57 to 0.49)Pain free grip strength affected arm SMD (95%) M-SilvestriniM-Silvestrini0.14 (-0.39 to 0.68)Pain SMD (95% Cl) - negative value favours treatment M-SilvestriniM-Silvestrini0.14 (-0.39 to 0.68)Pain free grip strength affected arm SMD (95% Cl) M-SilvestriniM-Silvestrini0.34 (-0.88 to 0.20)Pain free grip strength affected arm SMD (95% Cl) M-SilvestriniDASH score (b-100, 100 most complaints, negative value favours treatment)SMDM-Silvestrini0.14 (-0.39 to 0.68)DASH score (b-100, 100 most complaints, negative value favour					
Heterogeneity $p > 65\%$ $p = 0.39$ $p = 0.18$ Pain free grip strength ratio affected/ unaffected arm SMD (95%) Bisset $0.76 (0.39 to 1.13)^*$ $0.20 (-0.47 to 0.56)$ $0.17 (-0.1)^*$ Exercise vs no interventionDASH score (0-100, 100 most complaints, negative value favours treatment) SMD PetersonPain on maximum voluntary contraction SMD (95% Cl) - negative value favours tre PetersonO.30 (-0.74 to 0.40)Pain on maximum muscular elongation SMD (95% Cl) - negative value favours tre PetersonO.24 (-0.68 to 0.19)Eccentric excercise and stretching vs stretchingDASH score (0-100, 100 most complaints, negative value favours treatment) SMD M-SilvestriniO.07 (-0.46 to 0.60)Pain SMD (95% Cl) - negative value favours treatment M-SilvestriniO.024 (-0.68 to 0.19)Pain free grip strength affected arm SMD (95%) M-SilvestriniO.07 (-0.46 to 0.60)Pain free grip strength affected arm SMD (95%) M-SilvestriniO.26 (-0.79 to 0.27)Concentric excercise and stretching vs stretchingDASH score (0-100, 100 most complaints, negative value favours treatment) SMD M-SilvestriniO.24 (-0.68 to 0.69)Pain free grip strength affected arm SMD (95%) M-SilvestriniO.26 (-0.79 to 0.27)Concentric excercise and stretching vs tretchingMD (95% Cl) - negative value favours treatment M-Silvestrin			-1.27 (-1.74 to -0.79)*		
Bisset       0.76 (0.39 to 1.13)*       0.20 (-0.47 to 0.56)       0.17 (-0.14)         Exercise vs no intervention         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         Peterson       -0.03 (-0.47 to 0.40)       -         Pain on maximum voluntary contraction SMD (95% Cl) - negative value favours treatment)         Pain on maximum muscular elongation SMD (95% Cl) - negative value favours treatment)         Peterson       -0.24 (-0.68 to 0.19)         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment)         M-Silvestrini       -0.07 (-0.46 to 0.60)         M-Silvestrini       -0.04 (-0.57 to 0.49)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)         Pain SMD (95% Cl) - negative value favours treatment)         SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.26 (-0.79 to 0.27)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       0.14 (-0.39 to 0.68)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.34 (-0.88 to 0.20)			p>65%		p=0.18 l <sup>2</sup> =
Bisset       0.76 (0.39 to 1.13)*       0.20 (-0.47 to 0.56)       0.17 (-0.1)         Exercise vs no intervention         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         Peterson       -0.03 (-0.47 to 0.40)       -         Pain on maximum voluntary contraction SMD (95% Cl) - negative value favours treatment)         Pain on maximum muscular elongation SMD (95% Cl) - negative value favours treatment)         Peterson       -0.24 (-0.68 to 0.19)         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment)         M-Silvestrini       -0.07 (-0.46 to 0.60)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.02 (-0.79 to 0.27)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.14 (-0.39 to 0.68)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.34 (-0.88 to 0.20)         Pain free grip strength affected arm SMD (95% Cl)         M-Silvestrini       -0.34 (-0.88 to 0.20) <t< td=""><td>Pain f</td><td>free grip strength</td><td>n ratio affected/ unaffec</td><td>cted arm SMD (95%)</td><td></td></t<>	Pain f	free grip strength	n ratio affected/ unaffec	cted arm SMD (95%)	
DASH score (0-100, 100 most complaints, negative value favours treatment) SMC         Peterson       -0.03 (-0.47 to 0.40)       -       -         Pain on maximum voluntary contraction SMD (95% CI) - negative value favours tre         Peterson       -0.30 (-0.74 to 0.14)       -       -         Pain on maximum muscular elongation SMD (95% CI) - negative value favours tre         Peterson       -0.24 (-0.68 to 0.19)       -       -         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SMC         M-Silvestrini       -0.04 (-0.57 to 0.49)       -         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       0.14 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% CI)       M-Silvestrini       -					0.17 (-0.18 t
Peterson       -0.03 (-0.47 to 0.40)       -         Pain on maximum voluntary contraction SMD (95% Cl) - negative value favours tre         Peterson       -0.30 (-0.74 to 0.14)       -         Pain on maximum muscular elongation SMD (95% Cl) - negative value favours tree         Peterson       -0.24 (-0.68 to 0.19)       -         Peterson       -0.24 (-0.68 to 0.19)       -       -         Peterson       -0.24 (-0.68 to 0.60)       -       -         M-Silvestrini       -0.07 (-0.46 to 0.60)       -       -         M-Silvestrini       -0.04 (-0.57 to 0.49)       -       -         Pain SMD (95% Cl) - negative value favours treatment       M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching       -       -       -       -         DASH score (0-100, 100 most complaints, negative value favours treatment       M-Silvestrini       0.14 (-0.39 to 0.68) </td <td>Exercise vs r</td> <td>no intervention</td> <td></td> <td></td> <td></td>	Exercise vs r	no intervention			
Peterson       -0.03 (-0.47 to 0.40)       -         Pain on maximum voluntary contraction SMD (95% Cl) - negative value favours tre         Peterson       -0.30 (-0.74 to 0.14)       -         Pain on maximum muscular elongation SMD (95% Cl) - negative value favours tree         Peterson       -0.24 (-0.68 to 0.19)       -         Peterson       -0.24 (-0.68 to 0.19)       -       -         Peterson       -0.24 (-0.68 to 0.60)       -       -         M-Silvestrini       -0.07 (-0.46 to 0.60)       -       -         M-Silvestrini       -0.04 (-0.57 to 0.49)       -       -         Pain SMD (95% Cl) - negative value favours treatment       M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching       -       -       -       -         DASH score (0-100, 100 most complaints, negative value favours treatment       M-Silvestrini       0.14 (-0.39 to 0.68) </td <td>ПДСН</td> <td>l score (0-100-10</td> <td>0 most complaints per</td> <td>vative value favours tre</td> <td>atment) SMD //</td>	ПДСН	l score (0-100-10	0 most complaints per	vative value favours tre	atment) SMD //
Peterson       -0.30 (-0.74 to 0.14)       -         Pain on maximum muscular elongation SMD (95% Cl) - negative value favours tree         Peterson       -0.24 (-0.68 to 0.19)         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         M-Silvestrini       -0.07 (-0.46 to 0.60)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.07 (-0.46 to 0.60)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.04 (-0.57 to 0.49)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       0.14 (-0.39 to 0.68)         M-Silvestrini       0.14 (-0.39 to 0.68)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.34 (-0.88 to 0.20)         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)         M-Sil				-	-
Peterson       -0.30 (-0.74 to 0.14)       -         Pain on maximum muscular elongation SMD (95% Cl) - negative value favours tree         Peterson       -0.24 (-0.68 to 0.19)         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         M-Silvestrini       -0.07 (-0.46 to 0.60)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.07 (-0.46 to 0.60)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.04 (-0.57 to 0.49)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       0.14 (-0.39 to 0.68)         M-Silvestrini       0.14 (-0.39 to 0.68)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.34 (-0.88 to 0.20)         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)         M-Sil	Pain (	on maximum vol	untary contraction SMC	) (95% CI) - negative val	ue favours tres
Peterson       -0.24 (-0.68 to 0.19)       -         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       -0.07 (-0.46 to 0.60)       -         Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       -0.04 (-0.57 to 0.49)       -         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       0.14 (-0.39 to 0.68)       -         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% CI)       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -         M-Silvestrini       0.41 (-0.88 to 0.20)       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -	i ani c			-	-
Peterson       -0.24 (-0.68 to 0.19)       -         Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       -0.07 (-0.46 to 0.60)       -         Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       -0.04 (-0.57 to 0.49)       -         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       0.14 (-0.39 to 0.68)       -         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% CI)       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -         M-Silvestrini       0.41 (-0.88 to 0.20)       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -       -         Pain free grip strength affected arm SMD (95% CI)       -       -					
Eccentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         M-Silvestrini       -0.07 (-0.46 to 0.60)       -         Pain SMD (95% CI) - negative value favours treatment       M-Silvestrini       -0.04 (-0.57 to 0.49)       -         Pain free grip strength affected arm SMD (95%)       M-Silvestrini       -0.26 (-0.79 to 0.27)       -       -         Concentric excercise and stretching vs stretching       DASH score (0-100, 100 most complaints, negative value favours treatment) SMD       M-Silvestrini       0.14 (-0.39 to 0.68)       -       -         Pain SMD (95% CI) - negative value favours treatment       M-Silvestrini       0.41 (-0.13 to 0.95)       -       -         Pain SMD (95% CI) - negative value favours treatment       M-Silvestrini      41 (-0.88 to 0.20)       -       -         Pain SMD (95% CI) - negative value favours treatment       M-Silvestrini      041 (-0.88 to 0.20)       -       -         Pain free grip strength affected arm SMD (95% CI)       M-Silvestrini      041 (-0.88 to 0.20)       -       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support       Overall improvement RR (95% CI) - RR>1 favours treatment       Selvanetti       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% CI)       Selvanetti	Pain o		-	(95% CI) - negative valu	e favours treat
DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       -0.07 (-0.46 to 0.60)       -         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       -0.04 (-0.57 to 0.49)       -         Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       0.14 (-0.39 to 0.68)       -         M-Silvestrini       0.14 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% Cl)       -       -         Pain free grip strength affected arm SMD (95% Ci)       -       -         M-Silvestrini       0.41 (-0.13 to 0.95)       -       -         Pain free grip strength affected arm SMD (95% Ci)       -       -       -         M-Silvestrini       -0.34 (-0.88 to 0.20)       -       -       -         Verall improvement RR (95% Cl) - RR>1 favours treatment       Selvanetti       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       Selvanetti       4.45 (3.51 to 5.40)*       -       4.65 (3.68		Peterson	-0.24 (-0.68 to 0.19)		-
M-Silvestrini-0.07 (-0.46 to 0.60)-Pain SMD (95% Cl) - negative value favours treatment M-Silvestrini-0.04 (-0.57 to 0.49)-Pain free grip strength affected arm SMD (95%) M-Silvestrini-0.26 (-0.79 to 0.27)-M-Silvestrini-0.26 (-0.79 to 0.27)-Concentric excercise and stretching vs stretchingDASH score (0-100, 100 most complaints, negative value favours treatment) SME M-Silvestrini0.14 (-0.39 to 0.68)-Pain SMD (95% Cl) - negative value favours treatment M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci) M-SilvestriniPain free grip strength affected arm SMD (95% Cl) SelvanettiAffected arm SMD (95% Cl) SelvanettiAffected arm SMD (95% Cl) SelvanettiAffected arm SMD (95% Cl) SelvanettiAffected ar	Eccentric ex	cercise and stret	tching vs stretching		
M-Silvestrini-0.07 (-0.46 to 0.60)-Pain SMD (95% CI) - negative value favours treatmentM-Silvestrini-0.04 (-0.57 to 0.49)-Pain free grip strength affected arm SMD (95%)M-Silvestrini-0.26 (-0.79 to 0.27)-Concentric excercise and stretching vs stretchingDASH score (0-100, 100 most complaints, negative value favours treatment) SMEM-Silvestrini0.14 (-0.39 to 0.68)-Pain SMD (95% CI) - negative value favours treatmentM-Silvestrini0.14 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci)Pain free grip strength affected arm SMD (95% Ci)M-Silvestrini-0.34 (-0.88 to 0.20)-Pain free grip strength affected is no intervention (sham ultrasound, elbow supportOverall improvement RR (95% CI) - RR>1 favours treatmentSelvanetti-23.39 (3.38Pain on Ko-scale (larger value means less pain) SMD (95% CI)Selvanetti4.45 (3.51 to 5.40)*-	ΠΔςμ	H score (0-100 10	0 most complaints neg	vative value favours tre	atment) SMD (
M-Silvestrini-0.04 (-0.57 to 0.49)-Pain free grip strength affected arm SMD (95%) M-Silvestrini-0.26 (-0.79 to 0.27)-Concentric excercise and stretching vs stretchingDASH score (0-100, 100 most complaints, negative value favours treatment) SMD M-Silvestrini0.14 (-0.39 to 0.68)-Pain SMD (95% Cl) - negative value favours treatment M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci) M-SilvestriniPain free grip strength affected arm SMD (95% Ci) M-SilvestriniEccentric excercise and stretching vs no intervention (sham ultrasound, elbow supportOverall improvement RR (95% Cl) - RR>1 favours treatment Selvanetti-23.39 (3.38Pain on Ko-scale (larger value means less pain) SMD (95% Cl) Selvanetti4.45 (3.51 to 5.40)*-4.65 (3.68	DAGH			-	-
M-Silvestrini-0.04 (-0.57 to 0.49)-Pain free grip strength affected arm SMD (95%) M-Silvestrini-0.26 (-0.79 to 0.27)-Concentric excercise and stretching vs stretchingDASH score (0-100, 100 most complaints, negative value favours treatment) SMD M-Silvestrini0.14 (-0.39 to 0.68)-Pain SMD (95% CI) - negative value favours treatment M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci) M-SilvestriniPain free grip strength affected arm SMD (95% Ci) M-SilvestriniEccentric excercise and stretching vs no intervention (sham ultrasound, elbow supportOverall improvement RR (95% CI) - RR>1 favours treatment Selvanetti-23.39 (3.38Pain on Ko-scale (larger value means less pain) SMD (95% CI) Selvanetti4.45 (3.51 to 5.40)*-4.65 (3.68					
Pain free grip strength affected arm SMD (95%)         M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% Cl) - RR>1 favours treatment         Selvanetti       -       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.65 (3.68	Pain S		-	eatment	
M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SMD         M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% Cl) - RR>1 favours treatment         Selvanetti       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.65 (3.68		M-Silvestrini	-0.04 (-0.57 to 0.49)	-	-
M-Silvestrini       -0.26 (-0.79 to 0.27)       -         Concentric excercise and stretching vs stretching         DASH score (0-100, 100 most complaints, negative value favours treatment) SME         M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% Cl) - RR>1 favours treatment         Selvanetti       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.65 (3.68	Pain f	free grip strength	affected arm SMD (95	%)	
DASH score (0-100, 100 most complaints, negative value favours treatment) SMDM-Silvestrini0.14 (-0.39 to 0.68)-Pain SMD (95% Cl) - negative value favours treatment-M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci)-M-Silvestrini-0.34 (-0.88 to 0.20)-Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow supportOverall improvement RR (95% Cl) - RR>1 favours treatment Selvanetti-Pain on Ko-scale (larger value means less pain) SMD (95% Cl) Selvanetti4.65 (3.68				-	-
DASH score (0-100, 100 most complaints, negative value favours treatment) SMDM-Silvestrini0.14 (-0.39 to 0.68)-Pain SMD (95% CI) - negative value favours treatment-M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci)-M-Silvestrini-0.34 (-0.88 to 0.20)-Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow supportOverall improvement RR (95% CI) - RR>1 favours treatment Selvanetti-Selvanetti4.45 (3.51 to 5.40)*-4.65 (3.68					
M-Silvestrini       0.14 (-0.39 to 0.68)       -         Pain SMD (95% Cl) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% Cl) - RR>1 favours treatment         Selvanetti       -       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.65 (3.68		excercise and str	etching vs stretching		
Pain SMD (95% CI) - negative value favours treatment         M-Silvestrini       0.41 (-0.13 to 0.95)       -         Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% Cl) - RR>1 favours treatment         Selvanetti       -       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.65 (3.68	Concentric e				
M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci) M-Silvestrini-0.34 (-0.88 to 0.20)-Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow supportOverall improvement RR (95% Cl) - RR>1 favours treatment Selvanetti-23.39 (3.38Pain on Ko-scale (larger value means less pain) SMD (95% Cl) 4.45 (3.51 to 5.40)*-4.65 (3.68		l score (0-100, 10	00 most complaints, neg	gative value favours trea	atment) SMD (
M-Silvestrini0.41 (-0.13 to 0.95)-Pain free grip strength affected arm SMD (95% Ci) M-Silvestrini-0.34 (-0.88 to 0.20)-Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow supportOverall improvement RR (95% Cl) - RR>1 favours treatment Selvanetti-23.39 (3.38Pain on Ko-scale (larger value means less pain) SMD (95% Cl) Selvanetti4.45 (3.51 to 5.40)*-4.65 (3.68			00 most complaints, neg	gative value favours trea -	atment) SMD (! -
Pain free grip strength affected arm SMD (95% Ci)         M-Silvestrini       -0.34 (-0.88 to 0.20)         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% Cl) - RR>1 favours treatment         Selvanetti       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.45 (3.51 to 5.40)*       -       4.65 (3.68	DASH	M-Silvestrini	00 most complaints, neg 0.14 (-0.39 to 0.68)	-	atment) SMD ( -
M-Silvestrini       -0.34 (-0.88 to 0.20)       -         Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% CI) - RR>1 favours treatment         Selvanetti       -       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% Cl)       4.65 (3.68	DASH	<b>M-Silvestrini</b> SMD (95% Cl) - n	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr	-	atment) SMD (! - -
Eccentric excercise and stretching vs no intervention (sham ultrasound, elbow support         Overall improvement RR (95% CI) - RR>1 favours treatment         Selvanetti       -       -       23.39 (3.38         Pain on Ko-scale (larger value means less pain) SMD (95% CI)         Selvanetti       4.45 (3.51 to 5.40)*       -       4.65 (3.68	DASH	<b>M-Silvestrini</b> SMD (95% Cl) - n	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr	-	atment) SMD (! - -
Overall improvement RR (95% CI) - RR>1 favours treatment SelvanettiSelvanetti23.39 (3.38Pain on Ko-scale (larger value means less pain) SMD (95% CI) Selvanetti4.45 (3.51 to 5.40)*-4.65 (3.68	DASH Pain S	M-Silvestrini SMD (95% Cl) - n M-Silvestrini free grip strength	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95	- eatment -	atment) SMD (9 - -
Selvanetti         -         -         23.39 (3.38           Pain on Ko-scale (larger value means less pain) SMD (95% Cl)         4.45 (3.51 to 5.40)*         4.65 (3.68	DASH Pain S	M-Silvestrini SMD (95% Cl) - n M-Silvestrini free grip strength	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95	- eatment -	atment) SMD (! - -
Selvanetti         -         -         23.39 (3.38           Pain on Ko-scale (larger value means less pain) SMD (95% Cl)         4.45 (3.51 to 5.40)*         4.65 (3.68	DASH Pain S Pain f	M-Silvestrini SMD (95% Cl) - n M-Silvestrini free grip strength M-Silvestrini	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95 -0.34 (-0.88 to 0.20)	- eatment - % Ci) -	-
Pain on Ko-scale (larger value means less pain) SMD (95% Cl) Selvanetti 4.45 (3.51 to 5.40)* - 4.65 (3.68	DASH Pain S Pain f Eccentric ex	M-Silvestrini SMD (95% Cl) - no M-Silvestrini free grip strength M-Silvestrini ccercise and stret	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95 -0.34 (-0.88 to 0.20) cching vs no interventio	- eatment - % Ci) - n (sham ultrasound, ell	-
<b>Selvanetti</b> 4.45 (3.51 to 5.40)* - 4.65 (3.68	DASH Pain S Pain f Eccentric ex	M-Silvestrini SMD (95% Cl) - no M-Silvestrini free grip strength M-Silvestrini ccercise and stret all improvement	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95 -0.34 (-0.88 to 0.20) cching vs no interventio	- eatment - % Ci) - n (sham ultrasound, ell	- - bow support)
	DASH Pain S Pain f Eccentric ex Overa	M-Silvestrini SMD (95% Cl) - n M-Silvestrini free grip strength M-Silvestrini ccercise and stret all improvement Selvanetti	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95 -0.34 (-0.88 to 0.20) tching vs no interventic RR (95% Cl) - RR>1 favo -	- eatment - % Ci) - on (sham ultrasound, ell purs treatment -	- - bow support)
Grip strength on Ka-scale (larger value means greater strength) SMD (05% Cl)	DASH Pain S Pain f Eccentric ex Overa	M-Silvestrini SMD (95% Cl) - no M-Silvestrini free grip strength M-Silvestrini ccercise and stret all improvement Selvanetti on Ko-scale (larg	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95 -0.34 (-0.88 to 0.20) tching vs no interventic RR (95% CI) - RR>1 favo - er value means less pai	- eatment - % Ci) - on (sham ultrasound, ell purs treatment -	- - bow support) 23.39 (3.38 to
VID SUCHAU OF NO-SCALE DARGELVARDE THEADS ALEATED STEPPINT JAND 182% CIT	DASH Pain S Pain f Eccentric ex Overa	M-Silvestrini SMD (95% Cl) - no M-Silvestrini free grip strength M-Silvestrini ccercise and stret all improvement Selvanetti on Ko-scale (larg	00 most complaints, neg 0.14 (-0.39 to 0.68) egative value favours tr 0.41 (-0.13 to 0.95) n affected arm SMD (95 -0.34 (-0.88 to 0.20) tching vs no interventic RR (95% CI) - RR>1 favo - er value means less pai	- eatment - % Ci) - on (sham ultrasound, ell purs treatment -	-

\*: statistically significant (p<0.05)



## PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	in title
ABSTRACT			
2 Structured summary 3 4	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	in abstract
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
∯ Objectives ∮	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
5 Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Ø Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	8
3 Study selection 4	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-8
5 Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8-9
8 Data items 9	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8-9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	12
3 Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-10
4 5 5 6	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> for each meta-analysis.	8-10
o 8 ATJ-S35 tnemtrsqed ts 2 9		ysM on <mark>/moɔ.imd.nəqoimd//:diin</mark> moif bəbsolnwod. 2013. Downloaded from http://mojopen.2013-om/ on May Erasmushogeschool (e.g'' الكلود each weta-augiksis: (e.g'' الكلود each weta-augiksis:	l Ope

Page 37 of 65



10

## PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	17
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	na
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10, Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10-12, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12, Table 2
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	13-15, table 3,4 figure 2,3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	13-15. table 3,4, figure 2,3
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10,12,17
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	na
DISCUSSION	1		
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	15-16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18-19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	20



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

. A Group (2009). Preferred Rep. Page 2 c.

Protected by comparing and any technologies to technologies with a full and the second as. Erasmushogeschool AT-L23 Inemited as 7202.51 (% M or monopological and the form of t

### Abstract

### Objectives

To evaluate the current evidence for the efficacy of corticosteroid injection and non-

electrotherapeutic physiotherapy compared with control for treating lateral epicondylitis.

### Design

Systematic review.

### Setting

n/a

### Participants

We searched five databases in September 2012 for randomized, controlled studies with a minimum quality rating. Of 640 studies retrieved, eleven were included, representing 1161 patients of both sexes and all ages.

### Interventions

Corticosteroid injection and non-electrotherapeutic physiotherapy.

### **Outcome measures**

Relative risk (RR) or standardised mean difference (SMD) for overall improvement, pain and grip strength at 4 to 12, 26 and 52 weeks follow-up.

### Results

Corticosteroid injection gave a short-term reduction in pain vs no intervention or NSAIDs (SMD -1.43, 95% CI -1.64 to -1.23). At intermediate follow-up, we found an increase in pain (SMD 0.32, 95% CI 0.13 to 0.51), reduction in grip-strength (SMD -0.48, 95% CI -0.73 to -

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

0.24), and negative effect on overall improvement effect (RR 0.66 (0.53 to 0.81). For corticosteroid injection vs lidocaine injection, evidence was conflicting. At long-term follow up, there was no difference on overall improvement and grip strength, with conflicting evidence for pain. Manipulation and exercise vs no intervention showed beneficial effect at short-term follow-up (overall improvement RR 2.75, 95% CI 1.30 to 5.82), but no significant difference at intermediate or long-term. We found moderate evidence for a short- and long-term effect of eccentric exercise and stretching vs no intervention. For exercise vs no intervention and eccentric or concentric exercise and stretching vs stretching alone, we found moderate evidence of no short-term effect.

### Conclusions

Corticosteroid injections have a short-term beneficial effect on lateral epicondylitis, but a negative effect at intermediate term. Evidence on long-term effect is conflicting. Manipulation and exercise and exercise and stretching have a short-term effect, the latter also a long-term effect.

### **Trial registration**

None.

### **Article summary**

### Article focus

• What is the current evidence for the effect of treating lateral epicondylitis with corticosteroid injection or non-electrotherapeutic physiotherapy compared to control?

### Key Messages

- Corticosteroid injections have a short-term beneficial effect on lateral epicondylitis, but a negative effect at intermediate term. Evidence on long-term effect is conflicting.
- There is evidence for a short-term effect of manipulation and exercise and exercise and stretching, for the latter also on long-term.

### Strengths and limitations of this review

• We found overall few good quality studies on these treatments, making a metaanalysis possible only for a few studies and outcomes.

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

### Introduction

Lateral epicondylitis of the elbow is a frequently encountered complaint in general practice with an incidence of 4 - 7 per 1000 per year [1-3]. It is characterised by pain and tenderness over the lateral humeral epicondyle and pain on resisted dorsiflexion and radial deviation of the wrist. It is usually a self-limiting condition, often resolving in 6 to 12 months regardless of treatment, but complaints may last up to 2 years or longer [4]. Due to considerable pain and discomfort, many patients need time off from work.

Most authors attribute the condition to a lesion in the short radial extensor muscle [1, 5]. A recent study has found evidence of reduced hyperaemia measured with spectral and colour Doppler in lateral epicondylitis treated with corticosteroid injection, suggesting evidence of an inflammatory component [6]. Others, finding little evidence of inflammation have proposed the term "lateral epicondylalgia" for the condition [7].

Most patients with lateral epicondylitis are treated in general practice, and although a large number of treatments are in use, there is no consensus on which treatments are most effective. The Cochrane Library has reviewed several treatments. For topical NSAIDs and NSAIDs taken orally, the conclusion is that both may have a short term effect [8]. For extracorporeal shockwave therapy, a review of nine studies including 1000 patients found this treatment to have no effect [9]. For acupuncture [10], deep friction massage [11], orthosis [12] and surgery [13] the reviews were inconclusive due to few and methodologically weak studies.

Four review articles have been published on the effect of corticosteroid injections [14-17]. They found a short-term effect of corticosteroid injection, but no proven long-term effect, and one review found evidence of a negative long-term effect [15]. However, some of the reviews included non-controlled studies [14, 16] and non-randomised studies [16]. In one

### **BMJ Open**

Five reviews of physiotherapeutic interventions show that there are few published studies on the effect of non-electrotherapeutic treatment, and many have methodological weaknesses [16, 18-21]. Bisset et al. [18] found evidence that manipulation and exercise had a short term effect. Four other reviews [16, 19-21] found short-term effects of mobilisation, manipulation and exercise. Three of these reviews included non-randomised or non-controlled studies [16, 19, 21]. Most previous systematic reviews have included electrotherapeutic physiotherapy such as ultrasound and extra-corporeal shockwave [14, 16, 20, 21].

Since there is no established, well-documented treatment to which new treatments can be compared, the use of a control group is important. The natural course of the condition, where most patients eventually recover regardless of intervention, makes this even more necessary. In a comparison of two different treatments, any effect found may only reflect this natural course of recovery unless the treatments prove better than a control group with no treatment.

It has been shown that systematic reviews which include studies with low scores on internal validity may over-estimate effect sizes, thus introducing a potential bias to the review [22]. There may also be a problem using rating scales with heterogeneous criteria, including i.e. criteria related to external validity, interpretation or ethical issues [22, 23].

To address these issues, a new systematic review on non-electrotherapeutic physiotherapy and corticosteroid injection seemed warranted. We wanted to include only randomised studies with a control group with no treatment or studies in which the groups only differed in regards to the investigated treatment. An established quality rating scale would be used. We also wanted to review the most current evidence on the efficacy of corticosteroid injection, since previous reviews have differing conclusions on long-term effect.

### Objective

The aim of this review was to assess the current evidence for the efficacy of corticosteroid injection and non-electrotherapeutical physiotherapy compared with control in patients with tennis elbow.

### Methods

We followed the recommendations of the Cochrane Collaboration [24] and the PRISMA Group [25] in the search and report of this systematic review.

### **Study selection**

We used the following inclusion criteria:

### Study type

Randomized, controlled trials assessing treatments for lateral epicondylitis or tennis elbow were eligible for inclusion. The studies had to have at least one treatment group and one control group. We defined a control group as a group receiving no treatment (a wait-and-see approach), common treatments with expected or known moderate effect (advice, rest, NSAIDs, pain-killers) or the same treatment as the experimental group with the exception of the investigated treatment.

### Participants

All age groups with a clinical diagnosis of lateral epicondylitis were included without restriction on gender.

### Treatments

We searched for studies investigating or comparing the efficacy of one of the following treatments: corticosteroid injection, non-electrotherapeutic physiotherapy including stretching, mobilisation, manipulation, massage, exercise or home training. Studies on splinting, ultrasound, shock wave and other electrotherapeutic modalities were excluded.

### Outcome measures and follow up

At least one validated, patient-centred outcome was necessary. This could include outcomes important to the patient such as pain, range of movement, grip strength, work status and relevant functional questionnaires. We included only studies done in a clinical setting with at least four-week follow-up of treatment effect.

### Study quality assessment

We used the 11-item PEDro scale to assess the quality of the studies included in the review. This rating system closely resembles the Cochrane Collaboration Scoring system [24] and is based on the Delphi list, developed for quality assessment of randomised controlled trials by Verhagen et al. [26]. It has been used in several previously published reviews [15, 18, 19]. The PEDro scale assesses the internal and external validity of a study by addressing the issues of eligibility criteria, randomisation, allocation, blinding, statistics and data reporting. The reliability of this scale has been confirmed by Maher et al in 2003 [27]. The maximum score is 10, since item number one on the scale (specified eligibility criteria) is not counted.

A minimum score of 5 out of 10 points (50%) was chosen to be necessary for inclusion in the review, as inclusion of lower quality studies in a systematic review may overestimate the treatment effect of interventions [28]. Ten studies were independently assessed

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

by two researchers (MO, ØH) [29-38] and three studies were rated by both researchers together [39-41]. The final decision on PEDro score was reached by consensus.

### Search methods for identification of studies

#### Electronic searches

From October 2009 to January 2010, we searched the following databases for publications: Medline (Ovid and PubMed), EVSCO/Cinahl, Embase, Allied and Complimentary Medicine, The Physiotherapy Evidence Database (PEDro) and the Cochrane RCT register. The searches within each database were done without restrictions on dates or languages. We used free text, not MESH terms, in these searches, and the key terms used were "tennis elbow", "lateral epicondylitis", epicondylalgia, elbow, randomised, randomized, injection, corticosteroid, and physiotherapy. The Boolean operator AND was used to link diagnostic terms and treatment where applicable. An additional search was done in September 2012 to identify any recently published studies.

#### Searching other resources

Further search was done in the reference list of articles initially considered for review.

#### Selection of studies

The searches resulted in a number of studies potentially eligible for inclusion. Titles and abstracts were then read by two researchers independently (MO,  $\emptyset$ H) and potential studies were selected based on the inclusion criteria. The final decision on inclusion was made by consensus from reading the full-text documents.

### Data extraction and statistical analysis

The included studies were read in full text and assessed by two independent researchers (MO,

ØH). One article, published in Italian, was translated by a professional bureau [41]. A

#### **BMJ Open**

standardized set of data was extracted from each selected study and recorded using standardized forms. We calculated statistics using the statistical computing language R (www.r-project.org, The R Foundation for Statistical Computing, Vienna, Austria). We reported the results of the outcome measures for three different timings of follow-up, defined as short-term (four to 12 weeks after randomisation), intermediate term (six months after randomisation) and long-term (more than six months after randomisation). For dichotomous data, we calculated relative risk (RR) and 95% confidence intervals (CI) with the R-project library "epi.R", for continuous data the standardised mean difference (SMD) and 95% CI with the R-project library "compute.es". We pooled estimates when we found sufficient clinical and statistical homogeneity between trials using the I<sup>2</sup> statistic, defined as I<sup>2</sup> less than 65% [42].

Some studies did not report the mean, standard deviation or number of samples, which were necessary to calculate SMD. Additional calculations were then required. For Coombes [38], the median and the interquartile range (IQR) were given. We set the median as the mean value and the standard deviation was given by IQR/1.35 under the assumption of normal distribution. For Newcomer [33], the standard deviation was calculated by t-statistics obtained by the p-value and degrees of freedom. For Price [34], the t-statistics was obtained by the degrees of freedom and 95% probability. The standard deviation was estimated by the t-statistics, the mean value and upper/lower confidence intervals.

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For overall improvement, a RR larger than 1 favoured treatment, and was statistically significant if the CI excluded 1. We defined the effect as large for values larger than 2 or less than 0.5, medium between 0.5 and 0.8 and between 1.25 and 2 and small for values between 0.8 and 1.0 and between 1.0 and 1.25.

For continuous data, a positive or negative SMD favoured treatment depending on the outcome measures, ie. for pain a negative SMD favoured treatment and for grip strength a

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

positive SMD favoured treatment. SMD was statistically significant if the CI excluded zero. We defined the effect as large for SMD more than 0.8, medium between 0.5 and 0.8 and small for values less than 0.5. For outcomes that could not be pooled, we graded the strength of the scientific evidence as strong (consistent findings in several high-quality randomised controlled studies), moderate (one high-quality randomised controlled study), conflicting (inconsistent finding between many studies) or no evidence [43].

### Inter-rater reliability

The inter-rater reliability for the individual PEDro scores was assessed by calculating the intra-class correlation coefficient [44]. The R-project library "psych" was used for this calculation. A substantial inter-rater reliability was found (intra-class correlation coefficient 0.69 (0.15-0.91), p<0.01).

### **Results**

The search retrieved an initial 839 hits, representing 640 individual articles. The further selection process is outlined in Figure 1. 623 articles were excluded based on title and abstract in a preliminary review. 17 articles [29-37, 39, 41, 45-50] were then assessed using the full-text documents. Three were found not to be randomised controlled trials [45-47], two had a PEDro quality rating below 50% (Table 2) [37, 39] and three had a follow-up shorter than four weeks [48-50]. The additional search done in september 2012 retrieved two possible studies [40, 51], one of which was excluded for not having a control group [51]. A recently published study was also assessed [38] and a total of 11 studies were included in the final review [29-36, 38, 40, 41].

### **Included studies**

The characteristics and details of each study are given in Table 1. The included studies represented a total population of 1161 patients. Several studies had more than one treatment

### **BMJ Open**

The mean age of patients varied from 41 to 51 years and the female percentages varied from 35 to 63. There were large differences in duration of complaints at baseline between studies. Most had a duration of several weeks to months and only one stated a short duration [33]. Eight studies had control groups with no active treatment [29-31, 34-36, 38, 40], e.g. a wait-and-see group or NSAIDs. Two of these used lidocaine as a placebo injection [31, 34]. In the three other studies, the control and treatment groups both received similar active treatments, with the intervention group in addition receiving the treatment to be investigated [32, 33, 41].

Eight studies investigated corticosteroid injections, representing 925 patients [29-31, 33-36, 38]. Five different corticosteroids were used, with different dosages and injection techniques. The control groups received no active treatment in seven of the eight studies, in one study both the control and treatment group received additional exercise treatment [33]. Seven of the studies had a long-time follow up of 24 weeks or more [29-31, 33-35, 38].

There were few studies covering non-electrotherapeutic physiotherapy. We found five studies which could be included, representing 600 patients [29, 32, 38, 40, 41]. The treatment modalities investigated were manipulation and exercise [29, 38], concentric or eccentric exercises [32], exercise [40] and eccentric exercises with stretching [41]. Three studies had a control group with no active treatment [29, 38, 40], the other two had control groups that received stretching and orthosis respectively. Three studies [29, 38, 41] had a follow up of 24 weeks or more.

The most frequently used outcome measures were assessment of pain and grip strength. Six studies measured pain free grip strength with handheld dynamometers [29-33,

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

Erasmushogeschool

35]. Eight studies used a number of different questionnaires covering pain, function and disability [29-33, 35, 38, 40]. Nine studies assessed pain on a visual analogue scale or Likert-scale [29-34, 36, 38, 40], and six studies rated patient's assessment of improvement on graded scales [29, 30, 35, 36, 38, 41].

### Risk of bias in included studies

We addressed the issues of the quality of the included studies and completeness of reported data by rating them with the PEDro scale (Table 2). Most studies used a computerized randomisation schedule, and seven of the eleven studies used concealed allocation [29-31, 35, 38, 40, 41]. Baseline comparison was done in all studies, the dropout rate was below 15% in ten studies [29, 30, 32-36, 38, 40, 41] and intention to treat analysis was stated in all studies. There was between-group analysis of at least one outcome measure in all the studies, and both point-measures and variations of outcome measures were reported in all studies.

The use of blinding was more diverse among the studies. Blinding the subject for treatment is difficult for physiotherapeutic treatments, but the use of blinded assessors reduces the risk of bias. None of the studies on physiotherapy in our review had blinded subjects or therapists, but two used blinded assessors [29, 38]. This might give biased results in the studies covering physiotherapeutic treatments.

For the eight studies on corticosteroid injection, the number using blinding was larger. There was blinding of subjects in four studies [31, 33, 34, 38], of the treating doctor in two [31, 33] and of assessors in six studies [29-31, 34, 35, 38].

In several studies the control group received some form of treatment (although similar to the treatment group) [32-34, 36, 41]. In these studies, synergistic effects between the treatments cannot be ruled out. This makes the results more difficult to interpret. Two studies had a short follow up of four and six weeks [32, 36], which for a condition usually lasting

#### **BMJ Open**

several months, reduces the clinical implication of the results. Difference in duration of complaints at baseline also complicates comparison between studies.

#### **Effects of interventions**

#### Corticosteroid injection

The efficacy of corticosteroid injection for treating lateral epicondylitis was investigated in eight studies (Table 3 and Figure 2 [52]). For short-term follow up, heterogeneity between studies made pooling of outcomes only possible for pain. For corticosteroid injection vs no intervention or NSAIDs, we found strong evidence for a beneficial effect on overall improvement and a large positive effect on pain [29, 30, 35, 36, 38]. For grip strength, we found moderate evidence for a negative effect [35]. For corticosteroid injection vs lidocaine injection, evidence was conflicting for effect on pain, with two studies showing a large positive effect (Price et al. using hydrocortisone and triamcinolone) [34] and one showing no significant difference [31]. For maximum grip strength, the evidence was also conflicting, with one study showing a large positive effect of treatment (Price et al. using triamcinolone)[34], and two studies showing no statistical difference (Lindenhovius, Price et al. using hydrocortisone) [31, 34]. For corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found moderate evidence for no significant difference on pain and grip strength [33].

At intermediate follow-up, we found sufficient homogeneity to poole estimates for overall improvement [29, 30, 38] and pain [29, 30, 35, 38] for corticosteroid injection vs. no intervention or NSAIDs. For overall improvement this showed a medium negative effect and for pain a small negative effect. For maximum grip strength, pooling of corticosteroid injection vs no intervention, NSAIDS and lidocaine showed a small negative effect [31, 34, 35]. For corticosteroid injection vs lidocaine injection, pooling of estimates was not possible due to heterogeneity. For pain, two studies showed a large negative effect (Price et al. using

hydrocortisone and triamcinolone)[34], and one study showed no significant difference [31], thus the evidence was conflicting. For grip strength, the evidence was also conflicting, with the same two studies showing a large negative effect [34] and one showing no significant difference [31]. For corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found moderate evidence of no significant effect on pain [33].

At long-term follow-up, pooled estimates of overall improvement showed no difference in effect of corticosteroid injection vs no intervention or NSAIDs [29, 30, 35, 38]. For pain, heterogeneity prevented pooling and we found the evidence conflicting with one study showing a large negative effect [30], and three others showing no significant difference in effect [29, 35, 38]. For grip strength, we found moderate evidence of no significant difference [35]. For corticosteroid injection vs lidocaine injection and corticosteroid injection, exercise and stretching vs exercise and stretching alone, we found no data on long-term effect.

### Physiotherapy

We included five studies (n=600) investigating non-electrotherapeutical physiotherapy, representing five different treatment modalities (Table 4 and Figure 3 [52]).

Two studies investigated the efficacy of manipulation and exercise vs. no intervention [29, 38]. At short-term, pooled estimates showed a large positive effect on overall improvement. For pain, pooling was not possible due to heterogeneity. We found strong evidence for a beneficial effect, for pain free grip strength we found moderate evidence for a beneficial effect. At intermediate-term, pooled estimates showed no difference between treatment and control for neither pain nor overall improvement. There was moderate evidence for no difference in pain free grip strength. At long-term, pooled estimates again showed no difference between treatment and control for either pain or improvement and we found moderate evidence for no difference in pain free grip strength.

#### **BMJ Open**

The efficacy of exercise vs no intervention was investigated in one study [40]. We found moderate evidence for no short-term difference in effect for outcomes on pain and DASH-score. There was no data on intermediate- or long-term effect.

For eccentric exercise and stretching vs stretching, investigated in one study [32], we found moderate evidence for no short-term treatment effect for outcomes on pain, pain-free grip strength and DASH-score. There was no data on intermediate- or long-term effect.

The same study also investigated the efficacy of concentric exercise and stretching vs stretching. We found moderate evidence for no short-term treatment effect for outcomes on pain, pain-free grip strength and DASH-score. There was no data on intermediate- or long-term effect.

Eccentric exercise and stretching vs no intervention was investigated in one study [41]. We found moderate evidence for a positive effect on pain and grip strength at short-term follow up. There was no data on efficacy at intermediate follow-up, but at long-term, we found moderate evidence of a positive effect on overall improvement, pain and grip strength.

### Discussion

### Summary of main results

This review found overall evidence for a short-term beneficial effect of corticosteroid injection. At intermediate follow-up, the evidence showed an overall negative effect. For corticosteroid injection vs lidocaine injection, we found the evidence to be conflicting. At long-term follow up, the evidence suggest no difference in effect on overall improvement and grip strength, but the evidence was conflicting for pain. For manipulation and exercise vs no intervention, we found an overall beneficial effect at short term, but no significant difference at intermediate or long-term follow-up. The evidence on exercise vs no intervention showed no differences at short-term follow up. For eccentric exercise and stretching vs stretching

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA

Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

alone, the evidence showed no short-term difference in effect. The same was found for concentric exercise and stretching vs stretching. The evidence on eccentric exercise and stretching vs no intervention showed a beneficial effect at short-term and long-term, while there was no data on intermediate follow-up.

For treating lateral epicondylitis, this review showed evidence for a short-term benefit of corticosteroid injection and manipulation with exercise. Eccentric exercise and stretching showed beneficial effect both at short- and long-term follow-up.

### Overall completeness and quality of the evidence

 There is a paucity of well-designed studies for determining the effect of nonelectrotherapeutic physiotherapy. The conclusions on the effect of these treatments are therefore limited. A comparison and review of several individual studies was only possible for one treatment modality, manipulation and exercise vs no intervention (Table 4).

We included eight studies treating a total of 925 patients with corticosteroid injections in our review. The conclusions for this treatment are more solid due to the larger number of studies, seven of which had long-term follow up. Due to differences in type of corticosteroids used, treatment regimes and outcome measures in the included studies, pooling of outcome measures was difficult. We found statistical heterogeneity for most outcomes, and pooling was only possible for a few of the outcomes and follow-ups. The long-term effect of corticosteroid injection showed conflicting results in the included studies. The large differences across the studies in duration of complaints at baseline, corticosteroids used in different dosages, and control group treatments may explain this.

The difference in duration of complaints at baseline complicates the interpretation and comparison of the results, since there might be different effects of the treatments on an epicondylitis of recent onset compared to one that has lasted several months. This is also reflected by Cook [53] who considered tendinopathy as a continuum with three stages and

### **BMJ Open**

different characteristics and presumably treatments for each stage. Haahr [54] found that high physical strain at work, work with manual tasks, high perceived stress at baseline and a high level of pain and dysfunction seem to predict an unfavourable outcome after one year. Thus any differences in baseline characteristic for these parameters might possibly influence between-group differences of outcome.

### Potential biases in the review process

The search process, selection of search terms and possible errors in reading and assessing the large number of articles represent a possible bias. Although we have searched several databases with a number of search terms, we may have missed some published studies. To reduce the risk of bias in the inclusion process, we used two reviewers who independently screened articles.

Our choice of inclusion criteria, especially the type of control or comparison treatment and the use of a cut-off quality score (PEDro), has important implications for the conclusions that can be drawn from this review. The efficacy of the treatments are here only compared with a control (no treatment) or to an underlying treatment that is common to both intervention groups, so no conclusion can be drawn on which of two different treatments is best.

To address the issue of publication bias, we searched two clinical trial registries: ClinicalTrial.gov (US National Institutes of Health) and Current Clinical Trials. We found no completed, unpublished studies on corticosteroid injection. Two completed studies on nonelectrotherapeutic physiotherapy were found. One from The United Kingdom completed in 2008 on manipulation with movement and one from Sweden completed in 2009 on eccentric training. We have found no published articles from these studies. Unpublished studies are not indexed in PubMed or other databases and older studies may have been conducted without

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

registration in a clinical trial registry, making it difficult to make an overall assessment of publication bias.

### Agreements and disagreements with other reviews

 Our findings agree with earlier reviews [14, 16, 17, 55]. We found consistent evidence of a beneficial short-term effect of corticosteroid injections, but evidence on the long-term effect is still conflicting. Coombes et al. [15] found in their review that corticosteroid injections have a worse outcome in the long term than most conservative interventions for tendinopathies of different locations. The included studies in our review did not allow for a similar strong conclusion on the long-term effect of corticosteroid injections. For non-electrotherapeutical physiotherapy, we agree with earlier reviews [14, 16, 18, 19, 21] that there is moderate evidence of a short-term effect of manipulation and exercise. Our review strengthens this conclusion with the inclusion of a recently published study [40]. In addition, we found moderate evidence of both short- and long-term beneficial effect of eccentric exercise and stretching.

### **Authors' conclusions**

#### Implications for practice

We found that both corticosteroid injection and manipulation with exercise gave a short-term benefit compared to control for treating lateral epicondylitis. At intermediate term, treatment with corticosteroid injection came out worse, while manipulation with exercise was not different from control. At long term, both treatments showed no benefit over control. For patients wanting treatment, it seems reasonable to recommend manipulation and exercise. For patients with mild symptoms, a wait-and-see approach would be appropriate. Though showing a large short-term benefit, the negative intermediate-term effect and uncertain longterm effect of corticosteroid injection make this treatment difficult to recommend. Eccentric

### **BMJ Open**

exercise with stretching showed efficacy both on short- and long-term follow-up, but only in one study.

### Implications for research

We found few studies and some conflicting results on the long-term efficacy of corticosteroid injection. More trials or a meta-analysis with individual patient data from earlier studies might give better answers to the question on long-term effect.

For non-electrotherapeutical physiotherapy, more studies with a randomised, controlled design are needed. Blinding, for example by using a blinded assessor, should be applied wherever possible. The promising results of manipulation with exercise and eccentric exercise with stretching need further investigating.

Future studies should differentiate between acute and chronic complaints. Baseline levels of perceived pain, stress levels, handedness and presence of physical stress at work should be recorded. Standardization in the usage of outcome measures will enable data pooling and meta-analyses in future reviews. Studies investigating the combined effect of physiotherapy and corticosteroid injection treatments would also be useful. Most patients with acute lateral epicondylitis are treated in a general practice setting, and future research should be performed in such a setting.

### Acknowledgements

Morten Olaussen and Oeystein Holmedal designed the study, performed the searches, read articles, decided which articles to include, performed the data extractions, interpreted the findings and wrote the main manuscript. Morten Lindbaek designed the study, decided which articles to include, interpreted the findings and revised the manuscript. Soeren Brage decided which articles to include, interpreted the findings and revised the manuscript. Hiroko Solvang

BMJ Open: first published as 10.1136/bmjopen-2013-003564 on 29 October 2013. Downloaded from http://bmjopen.bmj.com/ on May 15, 2025 at Department GEZ-LTA Erasmushogeschool . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

did the statistical calculations and analysis, interpreted the findings and revised the manuscript.

### **Competing interests**

The authors declare that they have no competing interests.

## Funding

Our work was funded by The Fund for General Practice Research, The Norwegian Medical Association, Oslo, Norway.

### References

- Chard MD, Hazleman BL: Tennis elbow--a reappraisal. *Br J Rheumatol* 1989,28(3):186-190.
- Hamilton PG: The prevalence of humeral epicondylitis: a survey in general practice.
   *JR CollGenPract* 1986,36(291):464-465.
- 3. Kivi P: The etiology and conservative treatment of humeral epicondylitis. *ScandJRehabilMed* 1983,**15(1)**:37-41.
- 4. Hudak PL, Cole DC, Haines AT: Understanding prognosis to improve rehabilitation: the example of lateral elbow pain. *ArchPhysMedRehabil* 1996,**77(6)**:586-593.
- 5. Murtagh J: Tennis elbow. *AustFamPhysician* 1984, **13(1)**:51.
- Torp-Pedersen TE, Torp-Pedersen ST, Qvistgaard E, Bliddal H: Effect of glucocorticosteroid injections in tennis elbow verified on colour Doppler ultrasonography: evidence of inflammation. *Br J Sports Med* 2008,42(12):978-982.
- Alfredson H, Lorentzon R: Chronic tendon pain: no signs of chemical inflammation but high concentrations of the neurotransmitter glutamate. Implications for treatment? *CurrDrug Targets* 2002,3(1):43-54.

### **BMJ Open**

8.	Pattanittum P, Turner T, Green S, Buchbinder R: Non-steroidal anti-inflammatory
	drugs (NSAIDs) for treating lateral elbow pain in adults. Cochrane Database of
	Systematic Reviews 2013, May 31: CD003686.
	Buchbinder R, Green S, Youd JM, Assendelft WJ, Barnsley L, Smidt N: Shock wave
	therapy for lateral elbow pain. Cochrane Database of Systematic Reviews 2009, Jan 21:
	CD003524.
).	Green S, Buchbinder R, Barnsley L, Hall S, White M, Smidt N, Assendelft W:
	Acupuncture for lateral elbow pain. Cochrane Database of Systematic Reviews
	2008,Oct 8:CD003527.
l.	Brosseau L, Casimiro L, Milne S, Robinson V, Shea B, Tugwell P, Wells G: Deep
	transverse friction massage for treating tendinitis. Cochrane Database of Systematic
	Reviews 2009, Jan 21: CD003528.
2.	Struijs PA, Smidt N, Arola H, van Dijk CN, Buchbinder R, Assendelft WJ: Orthotic
	devices for the treatment of tennis elbow. Cochrane Database of Systematic Reviews
	2009,Jan 21:CD001821.
8.	Buchbinder R, Green S, Bell SN, Barnsley L, Smidt N, Assendelft WJ, Johnston RV:
	Surgery for lateral elbow pain. Cochrane Database of Systematic Reviews 2011, Mar
	16:CD003525.
4.	Barr S, Cerisola FL, Blanchard V: Effectiveness of corticosteroid injections compared
	with physiotherapeutic interventions for lateral epicondylitis: a systematic review.
	<i>Physiotherapy</i> 2009, <b>95(4)</b> :251-265.
5.	Coombes BK, Bisset L, Vicenzino B: Efficacy and safety of corticosteroid injections
	and other injections for management of tendinopathy: a systematic review of
	randomised controlled trials. Lancet 2010,376(9754):1751-1767.

- 16. Nimgade A, Sullivan M, Goldman R: Physiotherapy, steroid injections, or rest for lateral epicondylosis? What the evidence suggests. Pain Pract 2005,5(3):203-215. 17. Smidt N, Assendelft WJ, Van der Windt DA, Hay EM, Buchbinder R, Bouter LM: Corticosteroid injections for lateral epicondylitis: a systematic review. Pain 2002,96(1-2):23-40. 18. Bisset L, Paungmali A, Vicenzino B, Beller E: A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia. BrJSports Med 2005,39(7):411-422. 19. Herd CR, Meserve BB: A systematic review of the effectiveness of manipulative therapy in treating lateral epicondylalgia. J Man Manip Ther 2008,16(4):225-237. 20. Smidt N, Assendelft WJ, Arola H, Malmivaara A, Greens S, Buchbinder R, Van der Windt DA, Bouter LM: Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. AnnMed 2003,35(1):51-62. Trudel D, Duley J, Zastrow I, Kerr EW, Davidson R, MacDermid JC: Rehabilitation 21. for patients with lateral epicondylitis: a systematic review. J Hand Ther 2004,17(2):243-266. 22. van Tulder MW, Suttorp M, Morton S, Bouter LM, Shekelle P: Empirical evidence of an association between internal validity and effect size in randomized controlled trials
  - 23. Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001,**323(7303)**:42-46.
  - Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2.: The Cochrane Collaboration; 2009.

of low-back pain. Spine (Phila Pa 1976) 2009,34(16):1685-1692.

### **BMJ Open**

25.	Moher D, Schulz KF, Altman DG: The CONSORT statement: revised
	recommendations for improving the quality of reports of parallel-group randomised
	trials. Lancet 2001,357(9263):1191-1194.
26.	Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild
	PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials
	for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol
	1998, <b>51(12)</b> :1235-1241.
27.	Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M: Reliability of the
	PEDro scale for rating quality of randomized controlled trials. Phys Ther
	2003, <b>83(8)</b> :713-721.
28.	Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP:
	Does quality of reports of randomised trials affect estimates of intervention efficacy
	reported in meta-analyses? Lancet 1998,352(9128):609-613.
29.	Bisset L, Beller E, Jull G, Brooks P, Darnell R, Vicenzino B: Mobilisation with
	movement and exercise, corticosteroid injection, or wait and see for tennis elbow:
	randomised trial. <i>BMJ</i> 2006, <b>333</b> :939.
30.	Hay EM, Paterson SM, Lewis M, Hosie G, Croft P: Pragmatic randomised controlled
	trial of local corticosteroid injection and naproxen for treatment of lateral epicondylitis
	of elbow in primary care. BMJ: British Medical Journal 1999,319(7215):964-968.
31.	Lindenhovius A, Henket M, Gilligan BP, Lozano-Calderon S, Jupiter JB, Ring D:
	Injection of dexamethasone versus placebo for lateral elbow pain: a prospective,
	double-blind, randomized clinical trial. Journal of Hand Surgery - American Volume
	2008, <b>33(6)</b> :909-919.
32.	Martinez-Silvestrini JA, Newcomer KL, Gay RE, Schaefer MP, Kortebein P, Arendt
	KW: Chronic lateral epicondylitis: comparative effectiveness of a home exercise

program including stretching alone versus stretching supplemented with eccentric or concentric strengthening. *Journal of hand therapy: official journal of the American Society of Hand Therapists* 2005,**18**:411-419, quiz.

- 33. Newcomer KL, Laskowski ER, Idank DM, McLean TJ, Egan KS: Corticosteroid injection in early treatment of lateral epicondylitis. *Clinical journal of sport medicine: officia ljournal of the Canadian Academy of Sport Medicine* 2001,**11**:214-222.
- Price R, Sinclair H, Heinrich I, Gibson T: Local injection treatment of tennis elbow hydrocortisone, triamcinolone and lignocaine compared. *BrJRheumatol* 1991,30(1):39-44.
- 35. Smidt N, Van der Windt DA, Assendelft WJ, Deville WL, Korthals-de Bos IB, Bouter LM: Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. *Lancet* 2002,**359(9307)**:657-662.
- 36. Toker S, Kilincoglu V, Aksakalli E, Gulcan E, Ozkan K: Short-term results of treatment of tennis elbow with anti-inflammatory drugs alone or in combination with local injection of a corticosteroid and anesthetic mixture. *Acta Orthopaedica et Traumatologica Turcica* 2008,42:184-187.
- 37. Tonks JH, Pai SK, Murali SR: Steroid injection therapy is the best conservative treatment for lateral epicondylitis: a prospective randomised controlled trial. *International Journal of Clinical Practice* 2007,61(2):240-246.
- 38. Coombes BK, Bisset L, Brooks P, Khan A, Vicenzino B: Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral epicondylalgia: a randomized controlled trial. *JAMA : the journal of the American Medical Association* 2013,309(5):461-469.
- 39. Kochar M, Dogra A: Effectiveness of a specific physiotherapy regimen on patients with tennis elbow: Clinical study. *Physiotherapy* 2002,**88(6)**:333-341.

### **BMJ Open**

40.	Peterson M, Butler S, Eriksson M, Svardsudd K: A randomized controlled trial of
	exercise versus wait-list in chronic tennis elbow (lateral epicondylosis). Upsala
	journal of medical sciences 2011, <b>116(4)</b> :269-279.
1.	Selvanetti A, Barrucci A, Antonaci A, Martinez P, Marra S, Necozione S: Role of the
	eccentric exercise in the functional reeducation of lateral epicondylitis: a randomised
	controlled clinical trial. Medicina dello Sport 2003,56:103-113.
2.	Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-
	analyses. BMJ 2003,327(7414):557-560.
	van Tulder M, Furlan A, Bombardier C, Bouter L: Updated method guidelines for
	systematic reviews in the cochrane collaboration back review group. Spine
	2003, <b>28(12)</b> :1290-1299.
ļ.	Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability.
	Psychological bulletin 1979,86(2):420-428.
	Altay T, Gunal I, Ozturk H: Local injection treatment for lateral epicondylitis.
	<i>ClinOrthopRelat Res</i> 2002,( <b>398</b> ):127-130.
	Croisier JL, Foidart-Dessalle M, Tinant F, Crielaard JM, Forthomme B: An isokinetic
	eccentric programme for the management of chronic lateral epicondylar tendinopathy.
	Br J Sports Med 2007,41(4):269-275.
7.	Dogramaci Y, Kalaci A, Savas N, Duman IG, Yanat AN: Treatment of lateral
	epicondilitis using three different local injection modalities: A randomized prospective
	clinical trial. Archives of Orthopaedic and Trauma Surgery 2009,129(10):1409-1414.
8.	Paungmali A, O'Leary S, Souvlis T, Vicenzino B: Hypoalgesic and
	sympathoexcitatory effects of mobilization with movement for lateral epicondylalgia.
	<i>PhysTher</i> 2003, <b>83(4)</b> :374-383.

49. Saartok T, Eriksson E: Randomized trial of oral naproxen or local injection of betamethasone in lateral epicondylitis of the humerus. Orthopedics 1986,9:191-194.

- 50. Vicenzino B, Paungmali A, Buratowski S, Wright A: Specific manipulative therapy treatment for chronic lateral epicondylalgia produces uniquely characteristic hypoalgesia. Manual Therapy 2001,6(4):205-212.
- 51. Viswas R, Ramachandran R, Korde Anantkumar P: Comparison of effectiveness of supervised exercise program and Cyriax physiotherapy in patients with tennis elbow (lateral epicondylitis): a randomized clinical trial. *TheScientificWorldJournal* 2012,012:939645.
- Neveloff JL, Fuchs SC, Moreira LB: Meta-analyses and Forest plots using a microsoft 52. excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC *research notes* 2012,**5**:52.
- 53. Cook JL, Purdam CR: Is tendon pathology a continuum? A pathology model to explain the clinical presentation of load-induced tendinopathy. Br J Sports Med 2009,43(6):409-416.
- 54. Haahr JP, Andersen JH: Prognostic factors in lateral epicondylitis: a randomized trial with one-year follow-up in 266 new cases treated with minimal occupational intervention or the usual approach in general practice. *Rheumatology (Oxford)* 2003,42(10):1216-1225.
- 55. Gaujoux-Viala C, Dougados M, Gossec L: Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2009,68(12):1843-1849.

### **BMJ Open**

## **FIGURES AND TABLES**

uploaded as web only data:

 Table 1: Demographics, treatments and outcome measures in the ten included studies

 Table 2: Quality rating of included studies by assessing internal and external validity with the PEDro scale

 Table 3: Effect size of improvement rate, reduction in pain and increase in grip

 strength for corticosteroid injection

 Table 4: Effect size of treatment effects for non-electrotherapeutic physiotherapy

Figure 1: Outline of the selection process

Figure 2: Forest-plot of effect sizes for corticosteroid injection

Figure 3: Forest-plot of effect sizes for non-electrotherapeutic physiotherapy